

Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β -lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and *Pseudomonas aeruginosa* with Difficult-to-Treat Resistance (DTR-*P. aeruginosa*)

Pranita D. Tamma,¹ Samuel L. Aitken,² Robert A. Bonomo,³ Amy J. Mathers,⁴ David van Duin,⁵ and Cornelius J. Clancy⁶

¹Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; ²Department of Pharmacy, University of Michigan Health, Ann Arbor, Michigan, USA; ³Medical Service and Center for Antimicrobial Resistance and Epidemiology, Louis Stokes Cleveland Veterans Affairs Medical Center, University Hospitals Cleveland Medical Center and Departments of Medicine, Pharmacology, Molecular Biology, and Microbiology, Case Western Reserve University, Cleveland, Ohio, USA; ⁴Departments of Medicine and Pathology, University of Virginia, Charlottesville, Virginia, USA; ⁵Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA; and ⁶Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Background. The Infectious Diseases Society of America (IDSA) is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. The initial guidance document on infections caused by extended-spectrum β -lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and *Pseudomonas aeruginosa* with difficult-to-treat resistance (DTR-*P. aeruginosa*) was published on 17 September 2020. Over the past year, there have been a number of important publications furthering our understanding of the management of ESBL-E, CRE, and DTR-*P. aeruginosa* infections, prompting a rereview of the literature and this updated guidance document.

Methods. A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections reviewed, updated, and expanded previously developed questions and recommendations about the treatment of ESBL-E, CRE, and DTR-*P. aeruginosa* infections. Because of differences in the epidemiology of resistance and availability of specific anti-infectives internationally, this document focuses on the treatment of infections in the United States.

Results. Preferred and alternative treatment recommendations are provided with accompanying rationales, assuming the causative organism has been identified and antibiotic susceptibility results are known. Approaches to empiric treatment, duration of therapy, and other management considerations are also discussed briefly. Recommendations apply for both adult and pediatric populations.

Conclusions. The field of antimicrobial resistance is highly dynamic. Consultation with an infectious diseases specialist is recommended for the treatment of antimicrobial-resistant infections. This document is current as of 24 October 2021. The most current versions of IDSA documents, including dates of publication, are available at www.idsociety.org/practice-guideline/amr-guidance/.

Keywords. ceftolozane-tazobactam; ceftazidime-avibactam; cefiderocol; imipenem-cilastatin-relebactam; meropenem-vaborbactam.

The rise in antimicrobial resistance (AMR) continues to be a global crisis. Collectively, antimicrobial-resistant pathogens caused more than 2.8 million infections and over 35 000 deaths annually from 2012 through 2017, according to the 2019 Centers for Disease Control and Prevention (CDC)

Antibiotic Resistance Threats in the United States Report [1]. The Infectious Diseases Society of America (IDSA) identified the development and dissemination of clinical practice guidelines and other guidance products for clinicians as a top initiative in its 2019 Strategic Plan [2]. IDSA acknowledged that the ability to address rapidly evolving topics such as AMR was limited by prolonged timelines needed to generate new or updated clinical practice guidelines, which are based on systematic literature reviews and rigorous GRADE (Grading of Recommendations Assessment, Development, and Evaluation) methodology. As an alternative to practice guidelines, IDSA endorsed developing more narrowly focused guidance documents for the treatment of difficult-to-manage infections. Guidance documents are prepared by a small team

Received 07 March 2022; editorial decision 07 March 2022; accepted 04 April 2022; published online 27 June 2022

Correspondence: P. D. Tamma, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA (ptamma1@jhmi.edu).

Clinical Infectious Diseases® 2022;75(2):187–212

© The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

<https://doi.org/10.1093/cid/ciac268>

of experts, who answer questions about treatment based on a comprehensive (but not necessarily systematic) review of the literature, clinical experience, and expert opinion. Documents do not include formal grading of evidence, and they are made available and updated at least annually online.

In the present document, guidance is provided on the treatment of infections caused by extended-spectrum β -lactamase-producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and *Pseudomonas aeruginosa* with difficult-to-treat resistance (DTR-*P. aeruginosa*) [3]. These pathogens have been designated urgent or serious threats by the CDC [1]. Each pathogen causes a wide range of infections that are encountered in US hospitals of all sizes and that carry with them significant morbidity and mortality.

Guidance is presented in the form of answers to a series of clinical questions for each pathogen. Although brief descriptions of notable clinical trials, resistance mechanisms, and susceptibility testing methods are included, this document does not provide a comprehensive review of these topics. Due to differences in the molecular epidemiology of resistance and availability of specific anti-infectives internationally, treatment recommendations are geared toward antimicrobial-resistant infections in the United States. The content of this document is current as of 24 October 2021; updates will be provided annually.

METHODS

IDSA convened a panel of 6 actively practicing infectious diseases specialists with clinical and research expertise in the treatment of antimicrobial-resistant bacterial infections. Through a series of virtual meetings, the panel developed commonly encountered treatment questions and corresponding answers for each pathogen group. Answers include a brief discussion of the rationale supporting the recommendations. This guidance document applies to both adult and pediatric populations. Suggested antibiotic dosing for adults with antimicrobial-resistant infections, assuming normal renal and hepatic function, is provided in [Table 1](#).

GENERAL MANAGEMENT RECOMMENDATIONS

Treatment recommendations in this guidance document assume that the causative organism has been identified and that in vitro activity of antibiotics is demonstrated. Assuming 2 antibiotics are equally effective, safety, cost, convenience, and local formulary availability are important considerations in selecting a specific agent. The panel recommends that infectious diseases specialists and physician or pharmacist members of the local antibiotic stewardship program are involved in the management of patients with infections caused by antimicrobial-resistant organisms.

In this document, the term complicated urinary tract infection (cUTI) refers to UTIs occurring in association with a structural or functional abnormality of the genitourinary tract, or any UTI in an adolescent or adult male. In general, the panel suggests cUTI be treated with similar agents and for similar treatment durations as pyelonephritis. For cUTI where the source has been controlled (eg, removal of a Foley catheter) and ongoing concerns for urinary stasis or indwelling urinary hardware are no longer present, it is reasonable to select antibiotic agents and treatment durations similar to uncomplicated cystitis.

Empiric Therapy

Empiric treatment decisions should be guided by the most likely pathogens, severity of illness of the patient, the likely source of the infection, and any additional patient-specific factors (eg, severe penicillin allergy, chronic kidney disease). When determining empiric treatment for a given patient, clinicians should also consider: (1) previous organisms identified from the patient and associated antibiotic susceptibility data in the last 6 months, (2) antibiotic exposures within the past 30 days, and (3) local susceptibility patterns for the most likely pathogens. Empiric decisions should be refined based on the identity and susceptibility profile of the pathogen.

Duration of Therapy and Transitioning to Oral Therapy

Recommendations on durations of therapy are not provided, but clinicians are advised that the duration of therapy should not differ for infections caused by organisms with resistant phenotypes compared to infections caused by more susceptible phenotypes. After antibiotic susceptibility results are available, it may become apparent that inactive antibiotic therapy was initiated empirically. This may impact the duration of therapy. For example, cystitis is typically a mild infection [4]. If an antibiotic not active against the causative organism was administered empirically for cystitis, but clinical improvement nonetheless occurred, the panelists agree that it is generally not necessary to repeat a urine culture, change the antibiotic regimen, or extend the planned treatment course. However, for all other infections, if antibiotic susceptibility data indicate a potentially inactive agent was initiated empirically, a change to an active regimen for a full treatment course (dated from the start of active therapy) is recommended. Additionally, important host factors related to immune status, ability to attain source control, and general response to therapy should be considered when determining treatment durations for antimicrobial-resistant infections, as with the treatment of any bacterial infection. Finally, whenever possible, oral step-down therapy should be considered, particularly if the following criteria are met: (1) susceptibility to an appropriate oral agent is demonstrated, (2) the patient is hemodynamically stable, (3) reasonable source control measures have occurred, and

Table 1. Suggested Dosing of Antibiotics for the Treatment of Infections Caused by Antimicrobial-Resistant Organisms

Agent	Adult Dosage (Assuming Normal Renal and Liver Function ^a)	Target Organisms ^{b,c}
Amikacin	Cystitis: 15 mg/kg/dose ^d IV once All other infections: 20 mg/kg/dose ^d IV × 1 dose, subsequent doses and dosing interval based on pharmacokinetic evaluation	ESBL-E, AmpC-E, CRE, DTR- <i>P. aeruginosa</i>
Ampicillin-sulbactam	9 g IV q8h over 4 h OR 27 g IV q24h as a continuous infusion For mild infections caused by CRAB isolates susceptible to ampicillin-sulbactam, it is reasonable to administer 3 g IV q4h – particularly if intolerance or toxicities preclude the use of higher dosages.	CRAB
Cefepime	Cystitis: 1 g IV q8h All other infections: 2 g IV q8h, infused over 3 h	AmpC-E
Cefiderocol	2 g IV q8h, infused over 3 h	CRE, DTR- <i>P. aeruginosa</i> , CRAB, <i>S. maltophilia</i>
Ceftazidime-avibactam	2.5 g IV q8h, infused over 3 h	CRE, DTR- <i>P. aeruginosa</i>
Ceftazidime-avibactam and aztreonam	Ceftazidime-avibactam: 2.5 g IV q8h, infused over 3 h PLUS Aztreonam: 2 g IV q8h, infused over 3 h, administered at the same time as ceftazidime-avibactam, if possible	Metallo-β-lactamase-producing CRE, <i>S. maltophilia</i>
Ceftolozane-tazobactam	Cystitis: 1.5 g IV q8h, infused over 1 h All other infections: 3 g IV q8h, infused over 3 h	DTR- <i>P. aeruginosa</i>
Ciprofloxacin	ESBL-E or AmpC infections: 400 mg IV q8h-q12h OR 500–750 mg PO q12h	ESBL-E, AmpC-E
Colistin	Refer to international consensus guidelines on polymyxins ^e	CRE cystitis, DTR- <i>P. aeruginosa</i> cystitis, CRAB cystitis
Eravacycline	1 mg/kg/dose IV q12h	CRE, CRAB
Ertapenem	1 g IV q24h, infused over 30 min	ESBL-E, AmpC-E
Fosfomycin	Cystitis: 3 g PO × 1 dose	ESBL-E, <i>E. coli</i> cystitis
Gentamicin	Cystitis: 5 mg/kg/dose ^d IV once All other infections: 7 mg/kg/dose ^d IV × 1 dose, subsequent doses and dosing interval based on pharmacokinetic evaluation	ESBL-E, AmpC-E, CRE, DTR- <i>P. aeruginosa</i>
Imipenem-cilastatin	Cystitis (standard infusion): 500 mg IV q6h, infused over 30 min All other ESBL-E or AmpC-E infections: 500 mg IV q6h, infused over 30 min All other CRE and CRAB infections: 500 mg IV q6h, infused over 3 h	ESBL-E, AmpC-E, CRE, CRAB
Imipenem-cilastatin-relebactam	1.25 g IV q6h, infused over 30 min	CRE, DTR- <i>P. aeruginosa</i>
Levofloxacin	750 mg IV/PO q24h	ESBL-E, AmpC-E, <i>S. maltophilia</i>
Meropenem	Cystitis (standard infusion): 1 g IV q8h, infused over 30 min All other ESBL-E or AmpC-E infections: 1–2 g IV q8h, infused over 30 min All other CRE and CRAB infections: 2 g IV q8h, infused over 3 h	ESBL-E, AmpC-E, CRE, CRAB
Meropenem-vaborbactam	4 g IV q8h, infused over 3 h	CRE
Minocycline	200 mg IV/PO q12h	CRAB, <i>S. maltophilia</i>
Nitrofurantoin	Cystitis: Macrocrystal/monohydrate (Macrobid®) 100 mg PO q12h Cystitis: Oral suspension: 50 mg PO q6h	ESBL-E cystitis, AmpC-E cystitis
Plazomicin	Cystitis: 15 mg/kg ^d IV × 1 dose All other infections: 15 mg/kg ^d IV × 1 dose, subsequent doses and dosing interval based on pharmacokinetic evaluation	ESBL-E, AmpC-E, CRE, DTR- <i>P. aeruginosa</i>
Polymyxin B	Refer to international consensus guidelines on polymyxins ^e	DTR- <i>P. aeruginosa</i> , CRAB
Tigecycline	200 mg IV × 1 dose, then 100 mg IV q12h	CRE, CRAB, <i>S. maltophilia</i>
Tobramycin	Cystitis: 5 mg/kg/dose ^d IV × 1 dose All other infections: 7 mg/kg/dose ^d IV × 1 dose; subsequent doses and dosing interval based on pharmacokinetic evaluation	ESBL-E, AmpC-E, CRE, DTR- <i>P. aeruginosa</i>
Trimethoprim-sulfamethoxazole	Cystitis: 160 mg (trimethoprim component) IV/PO q12h Other infections: 8–12 mg/kg/day (trimethoprim component) IV/PO divided q8–12h (consider maximum dose of 960 mg trimethoprim component per day)	ESBL-E, AmpC-E, <i>S. maltophilia</i>

Abbreviations: AmpC-E, AmpC β-lactamase-producing Enterobacteriales; CRAB, carbapenem-resistant *Acinetobacter baumannii*; CRE, carbapenem-resistant Enterobacteriales; DTR-*P. aeruginosa*, *Pseudomonas aeruginosa* with difficult-to-treat resistance; *E. coli*, *Escherichia coli*; ESBL-E, extended-spectrum β-lactamase-producing Enterobacteriales; IV, intravenous; MIC, minimum inhibitory concentration; OR, odds ratio; PO, by mouth; q4h, every 4 hours; q6h, every 6 hours; q8h, every 8 hours; q12h, every 12 hours; q24h, every 24 hours; *S. maltophilia*, *Stenotrophomonas maltophilia*

Explanations/References

^aDosing suggested for several agents in table differs from dosing recommended by the US Food and Drug Administration.

^bTarget organisms limited to the following organisms and generally only after susceptibility has been demonstrated: ESBL-E, AmpC-E, CRE, DTR-*P. aeruginosa*, CRAB, and *S. maltophilia*.

^cFor additional guidance on the treatment of AmpC-E, CRAB, and *S. maltophilia*, refer to: <https://www.idsociety.org/practice-guideline/amr-guidance-2.0/>.

^dUse adjusted body weight for patients >120% of ideal body weight for aminoglycoside dosing.

^eTsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). *Pharmacotherapy* 2019; 39(1): 10–39.

(4) concerns about insufficient intestinal absorption are not present [5].

EXTENDED-SPECTRUM β -LACTAMASE-PRODUCING ENTEROBACTERIALES

The incidence of ESBL-E identified in bacterial cultures in the United States increased by 53% from 2012 to 2017, in large part due to increased community-acquired infections [6]. ESBLs are enzymes that inactivate most penicillins, cephalosporins, and aztreonam. ESBL-E generally remain susceptible to carbapenems. ESBLs do not inactivate non- β -lactam agents (eg, ciprofloxacin, trimethoprim-sulfamethoxazole, gentamicin). However, organisms carrying ESBL genes often harbor additional genes or mutations in genes that mediate resistance to a broad range of antibiotics.

Any gram-negative organism has the potential to harbor ESBL genes; however, they are most prevalent in *Escherichia coli*, *Klebsiella pneumoniae*, *Klebsiella oxytoca*, and *Proteus mirabilis* [7–9]. CTX-M enzymes, particularly CTX-M-15, are the most common ESBLs in the United States [8]. ESBLs other than CTX-M with unique hydrolyzing abilities are also present, including variants of narrow-spectrum TEM and SHV β -lactamases with amino acid substitutions, but have undergone less rigorous clinical investigation than CTX-M enzymes [10–13]. Routine ESBL testing is not performed by most clinical microbiology laboratories [14, 15]. Rather, non-susceptibility to ceftriaxone (ie, ceftriaxone minimum inhibitory concentrations [MICs] ≥ 2 mcg/mL) is often used as a proxy for ESBL production, although this threshold has limitations with specificity as organisms not susceptible to ceftriaxone for reasons other than ESBL production may be falsely presumed to be ESBL-producers [16, 17]. For this guidance document, ESBL-E will refer to presumed or confirmed ESBL-producing *E. coli*, *K. pneumoniae*, *K. oxytoca*, or *P. mirabilis*. Treatment recommendations for ESBL-E infections listed below assume that in vitro activity of preferred and alternative antibiotics has been demonstrated.

Question 1: What Are Preferred Antibiotics for the Treatment of Uncomplicated Cystitis Caused by ESBL-E?

Recommendation: Nitrofurantoin and trimethoprim-sulfamethoxazole are preferred treatment options for uncomplicated cystitis caused by ESBL-E.

Rationale

Nitrofurantoin and trimethoprim-sulfamethoxazole have been shown to be safe and effective options for uncomplicated cystitis, including uncomplicated ESBL-E cystitis [4, 18, 19]. Although carbapenems and the fluoroquinolones ciprofloxacin or levofloxacin are effective agents against ESBL-E cystitis [20, 21], their use for uncomplicated cystitis is discouraged when other safe and effective options are available. Limiting use of

these agents preserves their activity for future infections when treatment options may be more restricted. Moreover, limiting their use reduces the risk of associated toxicities, particularly with the fluoroquinolones, which have been associated with an increased risk for prolonged QTc intervals, tendinitis and tendon rupture, aortic dissections, seizures, peripheral neuropathy, and *Clostridioides difficile* infections, compared to other antibiotics [22–25].

Amoxicillin-clavulanate, single-dose aminoglycosides, and oral fosfomycin (for *E. coli* only) are alternative treatment options for uncomplicated ESBL-E cystitis. ESBL-E may test susceptible to amoxicillin-clavulanate and observational studies demonstrate clinical success with the use of amoxicillin-clavulanate for ESBL-E infections [26, 27]. A randomized controlled trial (RCT) compared a 3-day regimen of amoxicillin-clavulanate to a 3-day course of ciprofloxacin for 370 women with uncomplicated *E. coli* cystitis [20]. Clinical cure was observed in 58% and 77% of the women randomized to the amoxicillin-clavulanate and ciprofloxacin arms, respectively. The higher failure rates with amoxicillin-clavulanate appear associated with persistent vaginal bacterial colonization, which occurred in 45% and 10% of patients in the amoxicillin-clavulanate and ciprofloxacin arms, respectively [20]. The proportion of women in the trial infected with ESBL-E strains is not available, the panel suggests caution with the use of amoxicillin-clavulanate for the treatment of uncomplicated ESBL-E cystitis.

Aminoglycosides are nearly exclusively eliminated by the renal route in their active form. A single intravenous dose is generally effective for uncomplicated cystitis, with minimal toxicity, but robust clinical trial data are lacking [28].

Oral fosfomycin is an alternative agent exclusively for treatment of ESBL-producing *E. coli* uncomplicated cystitis as the *fosA* gene, intrinsic to *K. pneumoniae* and several other gram-negative organisms, can hydrolyze fosfomycin and may lead to clinical failure [29, 30]. Randomized controlled trial data indicate that oral fosfomycin is associated with higher clinical failure than nitrofurantoin for uncomplicated cystitis [18].

The panel does not recommend prescribing doxycycline for the treatment of ESBL-E cystitis. Two clinical outcomes studies, published more than 40 years ago, demonstrated that oral tetracyclines may be effective for the treatment of urinary tract infections (UTIs) [31, 32]. Both of these studies, however, primarily focused on *P. aeruginosa*, an organism not susceptible to oral tetracyclines, questioning the impact that antibiotic therapy had on clinical cure. Doxycycline is primarily eliminated through the intestinal tract and its urinary excretion is limited [33]. Until more robust data demonstrating the clinical effectiveness of oral doxycycline for the treatment of ESBL-E cystitis are available, the panel recommends against use of doxycycline for this indication. The roles of piperacillin-

tazobactam, cefepime, and the cephamycins for the treatment of uncomplicated cystitis are discussed in **Question 4**, **Question 5**, and **Question 6**.

Question 2: What Are Preferred Antibiotics for the Treatment of Pyelonephritis and Complicated Urinary Tract Infections Caused by ESBL-E?

Recommendation: Ertapenem, meropenem, imipenem-cilastatin, ciprofloxacin, levofloxacin, or trimethoprim-sulfamethoxazole are preferred treatment options for pyelonephritis and cUTIs caused by ESBL-E.

Rationale

Carbapenems, ciprofloxacin, levofloxacin, and trimethoprim-sulfamethoxazole are all preferred treatment options for patients with ESBL-E pyelonephritis and cUTIs based on the ability of these agents to achieve adequate and sustained concentrations in the urine, RCT results, and clinical experience [34–37]. If a carbapenem is initiated and susceptibility to ciprofloxacin, levofloxacin, or trimethoprim-sulfamethoxazole is demonstrated, transitioning to these agents is preferred over completing a treatment course with a carbapenem. Limiting use of carbapenem exposure will preserve their activity for future antimicrobial-resistant infections.

In patients in whom the potential for nephrotoxicity is deemed acceptable, once-daily aminoglycosides for a full treatment course are an alternative option for the treatment of pyelonephritis or cUTI [38]. Once-daily plazomicin was noninferior to meropenem in an RCT that included patients with pyelonephritis and cUTIs caused by the Enterobacterales [39]. Individual aminoglycosides are equally effective if susceptibility is demonstrated.

Nitrofurantoin and oral fosfomycin do not achieve adequate concentrations in the renal parenchyma and should be avoided for pyelonephritis and cUTI [40, 41]. However, fosfomycin is an alternative option for the treatment of prostatitis caused by ESBL-producing *E. coli* when preferred options (ie, carbapenems, fluoroquinolones, or trimethoprim-sulfamethoxazole) cannot be tolerated or do not test susceptible [42–44]. Fosfomycin, dosed at 3 g orally daily for 1 week, followed by 3 g orally every 48 hours for 6–12 weeks, was associated with clinical cure in 82% of patients in an observational study of 44 males with chronic bacterial prostatitis [42]. Fosfomycin should be avoided for prostatitis caused by gram-negative organisms other than *E. coli* (**Question 1**).

Doxycycline is not recommended for the treatment of ESBL-E pyelonephritis or cUTIs due to its limited urinary excretion and limited published comparative effectiveness studies (**Question 1**) [33]. The roles of piperacillin-tazobactam, cefepime, and the cephamycins for the treatment of pyelonephritis and cUTIs are discussed in **Question 4**, **Question 5**, and **Question 6**.

Question 3: What Are Preferred Antibiotics for the Treatment of Infections Outside of the Urinary Tract Caused by ESBL-E?

Recommendation: A carbapenem is preferred for the treatment of infections outside of the urinary tract caused by ESBL-E. After appropriate clinical response is achieved, transitioning to oral fluoroquinolones or trimethoprim-sulfamethoxazole should be considered, if susceptibility is demonstrated.

Rationale

A carbapenem is recommended as first-line treatment of ESBL-E infections outside of the urinary tract, based primarily on data from a large clinical trial [34]. The clinical trial randomized 391 patients with bloodstream infections due to ceftriaxone nonsusceptible *E. coli* or *K. pneumoniae* (87% later confirmed to have ESBL genes) to piperacillin-tazobactam 4.5 g intravenously every 6 hours or meropenem 1 g intravenously every 8 hours, both as standard infusions. The primary outcome of 30-day mortality occurred in 12% and 4% of patients receiving piperacillin-tazobactam and meropenem, respectively [34]. Trial data were subsequently reanalyzed only including patients with available clinical isolates against which piperacillin-tazobactam MICs were ≤ 16 mcg/mL by broth microdilution, the reference standard for antimicrobial susceptibility testing [45]. Reanalyzing the data from 320 patients, 30-day mortality was observed in 11% versus 4% of those in the piperacillin-tazobactam and meropenem arms, respectively. Although the absolute risk difference was attenuated and no longer significant in the reanalysis (ie, the 95% confidence interval ranged from –1% to 10%) [45], the panel still recommends carbapenem therapy as the preferred treatment of ESBL-producing bloodstream infections due to the overall direction of the risk difference. Comparable clinical trial data are not available for ESBL-E infections of other body sites. Nevertheless, the panel suggests extrapolating evidence for ESBL-E bloodstream infections to other common sites of infection, namely, pyelonephritis and cUTIs, intra-abdominal infections, skin and soft tissue infections, and pneumonia.

The role of oral step-down therapy for ESBL-E infections outside of the urinary tract has not been formally evaluated. However, oral step-down therapy has been shown to be a reasonable treatment consideration for Enterobacterales bloodstream infections, including those caused by antimicrobial-resistant isolates, after appropriate clinical milestones are achieved [46, 47]. Based on the known bioavailability and sustained serum concentrations of oral fluoroquinolones and trimethoprim-sulfamethoxazole, these agents should be treatment considerations for patients with ESBL-E infections if (1) susceptibility to 1 of these agents is demonstrated, (2) the patient is hemodynamically stable, (3) reasonable source control measures have occurred, and (4) concerns about insufficient intestinal absorption are not present [5].

Clinicians should avoid oral step-down to nitrofurantoin, fosfomycin, amoxicillin-clavulanate, doxycycline, or omadacycline for ESBL-E bloodstream infections. Nitrofurantoin and fosfomycin achieve poor serum concentrations [40, 41]. Amoxicillin-clavulanate and doxycycline achieve unreliable serum concentrations [33, 48]. Omadacycline is a tetracycline derivative with an oral formulation that may exhibit activity against ESBL-producing Enterobacterales isolates but has an unfavorable pharmacokinetic-pharmacodynamic profile [49, 50]. Until more clinical data are available investigating omadacycline's role for the treatment of ESBL-E infections, the panel recommends against its use for this indication.

Question 4: Is There a Role for Piperacillin-Tazobactam in the Treatment of Infections Caused by ESBL-E?

Recommendation: If piperacillin-tazobactam was initiated as empiric therapy for uncomplicated cystitis caused by an organism later identified as an ESBL-E and clinical improvement occurs, no change or extension of antibiotic therapy is necessary. The panel suggests carbapenems, fluoroquinolones, or trimethoprim-sulfamethoxazole rather than piperacillin-tazobactam for the treatment of ESBL-E pyelonephritis and cUTI, with the understanding that the risk of clinical failure with piperacillin-tazobactam may be low. Piperacillin-tazobactam is not recommended for the treatment of infections outside of the urinary tract caused by ESBL-E, even if susceptibility to piperacillin-tazobactam is demonstrated.

Rationale

Piperacillin-tazobactam demonstrates in vitro activity against a number of ESBL-E [51]. Observational studies have had conflicting results regarding the effectiveness of piperacillin-tazobactam for the treatment of ESBL-E infections. An RCT of ESBL-E bloodstream infections indicated inferior results with piperacillin-tazobactam compared to carbapenem therapy (Question 3) [34]. A second RCT investigating the role of piperacillin-tazobactam for the treatment of ESBL-E bloodstream infections is ongoing [52]. If piperacillin-tazobactam was initiated as empiric therapy for uncomplicated cystitis caused by an organism later identified as an ESBL-E and clinical improvement occurs, no change or extension of antibiotic therapy is necessary, as uncomplicated cystitis often resolves on its own. At least 3 observational studies have compared the efficacy of piperacillin-tazobactam and carbapenems for the treatment of ESBL-E pyelonephritis or cUTI [53–55]. The most robust observational study included 186 hospitalized patients from 5 hospitals with pyelonephritis or cUTI caused by *E. coli*, *K. pneumoniae*, *K. oxytoca*, or *P. mirabilis*, with confirmation of the presence of ESBL genes in all isolates. This study identified no difference in the resolution of clinical symptoms or 30-day mortality between the groups [53]. A randomized, open-label clinical trial investigating this question was also conducted [56]. The trial included 66 patients

with ESBL-producing *E. coli* pyelonephritis or cUTI (with confirmation of the presence of an ESBL gene) randomized to either piperacillin-tazobactam 4.5 g every 6 hours or ertapenem 1 g every 24 hours. Clinical success was similar between both groups at 94% for piperacillin-tazobactam and 97% for ertapenem. These studies suggest noninferiority between piperacillin-tazobactam and carbapenems for pyelonephritis or cUTIs.

In the subgroup of 231 patients with ESBL-E bloodstream infections from a urinary source in the aforementioned RCT comparing the outcomes of patients with *E. coli* or *K. pneumoniae* bloodstream infections treated with piperacillin-tazobactam or meropenem (Question 3), higher mortality was identified in the piperacillin-tazobactam group (7% vs 3%) [34], although it did not attain statistical significance. Although the panel is unable to state that piperacillin-tazobactam should be avoided for pyelonephritis or cUTIs, the panel continues to have concerns with the use of piperacillin-tazobactam for the treatment of ESBL-E infections, even if limited to UTIs, and prefers the use of carbapenem therapy (or oral fluoroquinolones or trimethoprim-sulfamethoxazole, if susceptible) [Question 2]).

Observational studies have had conflicting results regarding the effectiveness of piperacillin-tazobactam for the treatment of ESBL-E bloodstream infections [26, 53–66]. The effectiveness of piperacillin-tazobactam for the treatment of invasive ESBL-E infections may be diminished by the potential for organisms to have increased expression of the ESBL enzyme or by the presence of multiple β -lactamases [67]. Additionally, piperacillin-tazobactam MIC testing may be inaccurate and/or poorly reproducible when ESBL enzymes are present, or in the presence of other β -lactamase enzymes such as OXA-1, making it unclear if an isolate that tests susceptible to this agent is indeed susceptible [45, 68–71]. For these reasons, the panel recommends avoiding piperacillin-tazobactam for the treatment of invasive ESBL-E infections.

Question 5: Is There a Role for Cefepime in the Treatment of Infections Caused by ESBL-E?

Recommendation: Cefepime is not recommended for the treatment of nonurinary infections caused by ESBL-E, even if susceptibility to the agent is demonstrated. If cefepime was initiated as empiric therapy for uncomplicated cystitis caused by an organism later identified as an ESBL-E and clinical improvement occurs, no change or extension of antibiotic therapy is necessary. The panel recommends avoiding cefepime for the treatment of pyelonephritis and cUTI. Cefepime is also not recommended for the treatment of infections outside of the urinary tract caused by ESBL-E, even if susceptibility to cefepime is demonstrated.

Rationale

No clinical trials comparing the outcomes of patients with ESBL-E bloodstream infections treated with cefepime or

carbapenem have been conducted. Cefepime MIC testing may be inaccurate and/or poorly reproducible if ESBL enzymes are present [72]. If cefepime was initiated as empiric therapy for uncomplicated cystitis caused by an organism later identified as an ESBL-E and clinical improvement occurs, no change or extension of antibiotic therapy is necessary, as uncomplicated cystitis often resolves on its own. Limited data are available evaluating the role of cefepime versus carbapenems for ESBL-E pyelonephritis and cUTIs [56, 73]. A clinical trial evaluating the treatment of molecularly confirmed ESBL-E pyelonephritis and cUTI was terminated early because of a high clinical failure signal with cefepime (2 g intravenously every 12 hours), despite all isolates having cefepime MICs of 1–2 mcg/mL [56]. It is unknown if results would have been more favorable with 8-hour cefepime dosing. Until larger, more robust comparative effectiveness studies are available to inform the role of cefepime, the panel suggests avoiding cefepime for the treatment of ESBL-E pyelonephritis or cUTI.

Observational studies and a subgroup analysis of 23 patients in an RCT that compared cefepime and carbapenems for the treatment of invasive ESBL-E infections demonstrated either no difference in outcomes or poorer outcomes with cefepime [74–77]. For these reasons, the panel recommends avoiding cefepime for the treatment of invasive ESBL-E infections.

Question 6: Is There a Role for the Cephamycins in the Treatment of Infections Caused by ESBL-E?

Recommendation: Cephamycins are not recommended for the treatment of ESBL-E infections until more clinical outcomes data using ceftazidime or ceftolozane are available and optimal dosing has been defined.

Rationale

The cephamycins are cephalosporins that are generally able to retain in vitro activity against ESBL enzymes [78, 79]. The cephamycins available in the United States are ceftazidime and ceftolozane, which are both intravenous agents. At least 8 retrospective observational studies have compared the clinical outcomes of patients with ESBL-E infections—generally UTIs or bloodstream infections with urinary sources—treated with cephamycins versus carbapenems [80–87]. Six of the 8 investigations found no difference in clinical outcomes [80, 82–84, 86, 87], whereas 2 studies demonstrated poorer outcomes with cephamycins [81]. One of the 2 studies included 57 patients with *K. pneumoniae* bloodstream infections, 14-day mortality was 55% and 39% in the cephamycin and carbapenem arms, respectively [81]. The second study was the largest study published to date, including 380 patients with *E. coli* and *K. pneumoniae* bloodstream infections, and 30-day mortality was 29% versus 13% in the cephamycin and carbapenem arms, respectively [85]. Importantly, all 8 studies were generally small, included diverse sources of infection, had notable selection bias, and

used a variety of cephamycins with differences in dosing, duration, and frequency of administration.

The panel hesitates to recommend cephamycins for the treatment of ESBL-E infections, including ESBL-E uncomplicated cystitis. Many of the cephamycins investigated in observational studies are not available in the United States. Only 31 patients received ceftazidime (and none received ceftolozane) in published studies [83, 87]. The panel believes more clinical data with use of these agents for the treatment of ESBL-E infections is necessary before recommending their use—including optimal dosing and frequency of administration—especially in light of the 2 observational studies suggesting poorer clinical outcomes with cephamycin use. At least 1 study suggested favorable outcomes with high-dose, continuous infusion ceftazidime (ie, 6 g per day infused continuously) [87], which is challenging to administer. As both cephamycin and ceftazidime are only available intravenously and have relatively short half-lives, there does not appear to be a feasibility advantage with use of these agents over preferred agents for the treatment of ESBL-E infections.

CARBAPENEM-RESISTANT ENTEROBACTERIALES

CRE account for more than 13 000 nosocomial infections and contribute to greater than 1000 deaths in the United States annually [1]. The CDC defines CRE as members of the Enterobacterales order resistant to at least 1 carbapenem antibiotic or producing a carbapenemase enzyme [88]. Regarding bacteria that are intrinsically not susceptible to imipenem (eg, *Proteus* spp., *Morganella* spp., *Providencia* spp.), resistance to at least 1 carbapenem other than imipenem is required [88]. CRE comprise a heterogeneous group of pathogens with multiple potential mechanisms of resistance, broadly divided into those that are carbapenemase-producing and those that are not carbapenemase-producing. CRE that are not carbapenemase-producing may be the result of amplification of non-carbapenemase β -lactamase genes with concurrent outer membrane porin disruption [89]. Carbapenemase-producing isolates account for approximately 35–59% of CRE cases in the United States [90, 91].

The most common carbapenemases in the United States are *K. pneumoniae* carbapenemases (KPCs), which can be produced by any Enterobacterales. Other notable carbapenemases that have been identified in the United States include New Delhi metallo- β -lactamases (NDMs), Verona integron-encoded metallo- β -lactamases (VIMs), imipenem-hydrolyzing metallo- β -lactamases (IMPs), and oxacillinases (eg, OXA-48-like) [92, 93]. Knowledge of whether a CRE clinical isolate is carbapenemase-producing and, if it is, the specific carbapenemase produced is important in guiding treatment decisions.

Phenotypic tests such as the modified carbapenem inactivation method and the Carba NP test can differentiate carbapenemase-

and non-carbapenemase-producing CRE [94]. Molecular testing can identify specific carbapenemase families (eg, differentiating a KPC from an OXA-48-like carbapenemase). Carbapenemase phenotypic and/or genotypic testing are performed by a minority of clinical microbiology laboratories, but the panel strongly encourages all clinical microbiology laboratories to pursue carbapenemase testing to inform optimal treatment decisions. Treatment recommendations for CRE infections listed below assume that in vitro activity of preferred and alternative antibiotics has been demonstrated.

Question 1: What Are Preferred Antibiotics for the Treatment of Uncomplicated Cystitis Caused by CRE?

Recommendation: Ciprofloxacin, levofloxacin, trimethoprim-sulfamethoxazole, nitrofurantoin, or a single-dose of an aminoglycoside are preferred treatment options for uncomplicated cystitis caused by CRE. Standard infusion meropenem is a preferred treatment option for cystitis caused by CRE resistant to ertapenem (ie, ertapenem MICs ≥ 2 mcg/mL) but susceptible to meropenem (ie, meropenem MICs ≤ 1 mcg/mL), when carbapenemase testing results are either not available or negative. If none of the preferred agents are active, ceftazidime-avibactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, or cefiderocol are alternative options for uncomplicated CRE cystitis.

Rationale

Clinical trial data evaluating the efficacy of most preferred agents for uncomplicated CRE cystitis are not available. However, as ciprofloxacin, levofloxacin, trimethoprim-sulfamethoxazole, nitrofurantoin, or a single dose of an aminoglycoside all achieve high concentrations in urine, they are expected to be effective for uncomplicated CRE cystitis, when active [4, 18–21]. Meropenem is a preferred agent against uncomplicated CRE cystitis for isolates that remain susceptible to meropenem because most of these isolates do not produce carbapenemases [95]. Meropenem should be avoided if carbapenemase testing is positive, even if susceptibility to meropenem is demonstrated. There is uncertainty about the accuracy of meropenem MICs in these scenarios, and use of meropenem may lead to treatment failure [96]. Some agents listed as alternative options for ESBL-E cystitis (eg, fluoroquinolones) are recommended as preferred agents for CRE cystitis. These agents are not preferred agents for the treatment of uncomplicated ESBL-E cystitis in order to preserve their activity for more invasive infections. They are, however, preferred agents against uncomplicated CRE cystitis because there are generally fewer treatment options available for these infections.

Aminoglycosides are almost exclusively eliminated by the renal route in their active form. A single intravenous dose is generally effective for cystitis, with minimal toxicity [28].

Individual aminoglycosides are equally effective if susceptibility is demonstrated. In general, higher percentages of CRE clinical isolates are susceptible to amikacin and plazomicin than to other aminoglycosides [97, 98]. Plazomicin may remain active against isolates resistant to amikacin [99].

If none of the preferred agents is active, ceftazidime-avibactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, and cefiderocol are alternative options for uncomplicated CRE cystitis. Data are insufficient to favor 1 agent over the others, but all of these agents are reasonable treatment options based on published comparative effectiveness studies [100–105].

Fosfomycin use should be limited to uncomplicated CRE cystitis caused by *E. coli* as the *fosA* gene (intrinsic to certain gram-negative organisms such as *Klebsiella* spp., *Enterobacter* spp., and *Serratia marcescens*) can hydrolyze fosfomycin and may lead to clinical failure [29, 30]. Randomized controlled trial data indicate that oral fosfomycin is associated with higher clinical failure than nitrofurantoin for uncomplicated cystitis [18].

Colistin is an alternative agent for treating uncomplicated CRE cystitis only if none of the above agents is an option. Colistin converts to its active form in the urinary tract; clinicians should remain cognizant of the associated risk of nephrotoxicity [106]. Polymyxin B should not be used as treatment for uncomplicated CRE cystitis, due to its predominantly nonrenal clearance [107].

Question 2: What Are Preferred Antibiotics for the Treatment of Pyelonephritis and Complicated Urinary Tract Infections Caused by CRE?

Recommendation: Ciprofloxacin, levofloxacin, and trimethoprim-sulfamethoxazole are preferred treatment options for pyelonephritis and cUTI caused by CRE if susceptibility is demonstrated. Extended-infusion meropenem is a preferred treatment option for pyelonephritis and cUTIs caused by CRE resistant to ertapenem (ie, ertapenem MICs ≥ 2 mcg/mL) but susceptible to meropenem (ie, meropenem MICs ≤ 1 mcg/mL), when carbapenemase testing results are either not available or negative. Ceftazidime-avibactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, and cefiderocol are also preferred treatment options for pyelonephritis and cUTIs caused by CRE resistant to both ertapenem and meropenem.

Rationale

Although the minority of CRE are expected to retain susceptibility to ciprofloxacin, levofloxacin, or trimethoprim-sulfamethoxazole, these agents are all preferred agents to treat CRE pyelonephritis or cUTI after susceptibility is demonstrated [35–37].

Extended-infusion meropenem is a preferred agent against pyelonephritis and cUTI by CRE that remain susceptible to meropenem, because most of these isolates do not produce carbapenemases (Table 1) [90]. Meropenem should be avoided if carbapenemase testing is positive, even if susceptibility to

meropenem is demonstrated. There is uncertainty about the accuracy of meropenem MICs in these scenarios, and use of meropenem may lead to treatment failure [96].

Ceftazidime-avibactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, and cefiderocol are preferred treatment options for pyelonephritis and cUTIs caused by CRE resistant to both ertapenem and meropenem based on RCTs showing non-inferiority of these agents to common comparator agents for UTIs [100–105]. Data are insufficient to favor 1 agent over the others.

In patients in whom the potential for nephrotoxicity is deemed acceptable, once-daily aminoglycosides for a full treatment course are an alternative option [38]. Once-daily plazomicin was noninferior to meropenem in an RCT that included patients with pyelonephritis and cUTIs caused by the Enterobacteriales [39]. Individual aminoglycosides are equally effective if susceptibility is demonstrated. In general, higher percentages of CRE clinical isolates are susceptible to amikacin and plazomicin than to other aminoglycosides [97, 98]. Plazomicin may remain active against isolates resistant to amikacin [97, 98]. Nitrofurantoin and oral fosfomicin do not achieve adequate concentrations in the renal parenchyma and should be avoided for pyelonephritis and cUTI [40, 41].

Question 3: What Are Preferred Antibiotics for the Treatment of Infections Outside of the Urinary Tract Caused by CRE Resistant to Ertapenem but Susceptible to Meropenem, When Carbapenemase Testing Results Are Either Not Available or Negative?

Recommendation: Extended-infusion meropenem is the preferred treatment for infections outside of the urinary tract caused by CRE resistant to ertapenem (ie, ertapenem MICs ≥ 2 mcg/mL) but susceptible to meropenem (ie, meropenem MICs ≤ 1 mcg/mL), when carbapenemase testing results are either not available or negative.

Rationale

The panel believes that all clinical microbiology laboratories in the United States should develop approaches to detect carbapenemase production in CRE clinical isolates, including identifying the specific carbapenemase present (eg, KPC, NDM, OXA-48-like). The panel understands that most US clinical microbiology laboratories do not currently perform this testing and/or that there may be delays in identifying the presence of carbapenemases and in determining susceptibility to novel β -lactam agents (ie, ceftazidime-avibactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, cefiderocol). Therefore, an understanding of which novel agents may be active against CRE isolates is important.

Extended-infusion meropenem is recommended against infections outside of the urinary tract caused by CRE that remain susceptible to meropenem since most of these isolates do not produce carbapenemases [90]. Recommended dosing for extended-infusion meropenem is provided in Table 1. The

CDC characterized over 42 000 CRE isolates collected from all regions of the United States between 2017 and 2019 and found that only approximately 10% of CRE isolates containing a carbapenemase gene retained susceptibility to meropenem [108]. The panel recommends that meropenem be avoided if carbapenemase testing is positive, even if susceptibility to meropenem is demonstrated. Although studies indicating the optimal treatment approach when phenotypic-genotypic discordance exists are not available, the panel prefers to err on the side of caution.

Ceftazidime-avibactam is recommended as an alternative agent for the treatment of ertapenem-resistant, meropenem-susceptible CRE infections outside of the urinary tract (Question 4). The panel prefers to reserve ceftazidime-avibactam for the treatment of infections caused by CRE resistant to all carbapenems to preserve its activity. The panel recommends against the use of meropenem-vaborbactam or imipenem-cilastatin-relebactam to treat ertapenem-resistant, meropenem-susceptible infections caused by CRE since these agents are unlikely to offer any significant advantage beyond that of extended-infusion meropenem (ie, the addition of vaborbactam or relebactam is unlikely to provide any incremental benefit compared with a carbapenem alone).

Question 4: What Are the Preferred Antibiotics for the Treatment of Infections Outside of the Urinary Tract Caused by CRE Resistant to Both Ertapenem and Meropenem, When Carbapenemase Testing Results Are Either Not Available or Negative?

Recommendation: Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-cilastatin-relebactam are the preferred treatment options for infections outside of the urinary tract caused by CRE resistant to both ertapenem (ie, ertapenem MICs ≥ 2 mcg/mL) and meropenem (ie, meropenem MICs ≥ 4 mcg/mL), when carbapenemase testing results are either not available or negative. For patients with CRE infections who within the previous 12 months have received medical care in countries with a relatively high prevalence of metallo- β -lactamase-producing organisms or who have previously had a clinical or surveillance culture where a metallo- β -lactamase-producing isolate was identified, preferred treatment options include the combination of ceftazidime-avibactam plus aztreonam, or cefiderocol as monotherapy, if carbapenemase testing results are not available.

Rationale

CDC data from 2017 to 2019 indicate that approximately 35% of CRE clinical or surveillance isolates in the United States carry 1 of the main 5 carbapenemase genes [90]. Of these 35% of isolates, the specific prevalence by carbapenemase gene is as follows: *bla*_{KPC} (86%), *bla*_{NDM} (9%), *bla*_{VIM} (<1%), *bla*_{TMP} (1%), or *bla*_{OXA-48-like} (4%) [90]. A separate cohort of 1040 clinical and surveillance CRE isolates from across the United States

demonstrated that 59% of isolates were carbapenemase producing, with the distribution of carbapenemase genes relatively similar: *bla*_{KPC} (92%), *bla*_{NDM} (3%), *bla*_{VIM} (<1%), *bla*_{IMP} (<1%), and *bla*_{OXA-48-like} (3%) [91].

Ceftazidime-avibactam has activity against most KPC- and OXA-48-like-producing CRE [109, 110]. Meropenem-vaborbactam and imipenem-cilastatin-relebactam are active against most Enterobacterales that produce KPC enzymes but not those that produce OXA-48-like carbapenemases [111–119]. Neither ceftazidime-avibactam, meropenem-vaborbactam, nor imipenem-cilastatin-relebactam have activity against metallo- β -lactamase (eg, NDM)-producing Enterobacterales. As described above, the vast majority of CRE clinical isolates either do not produce carbapenemases or, if they do, produce KPCs. Therefore, all 3 of these agents (ie, ceftazidime-avibactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam) are preferred treatment options for CRE clinical isolates outside of the urinary tract caused by CRE resistant to both ertapenem and meropenem when carbapenemase testing results are either not available or negative. There are not data indicating differences in the effectiveness of these agents when susceptibility has been demonstrated (Question 5).

Previously, it was considered standard practice to administer extended-infusion meropenem in combination with a second agent, frequently polymyxins or aminoglycosides, for the treatment of infections caused by CRE isolates with meropenem MICs as high as 8–16 mcg/mL [120]. Data suggested that extended-infusion meropenem remained active against infections caused by organisms with carbapenem MICs in this range [121–123]. However, subsequent observational and RCT data indicate increased mortality and excess nephrotoxicity associated with polymyxin or aminoglycoside-based regimens relative to newer β -lactam- β -lactamase inhibitor agents for the treatment of CRE infections [124–132]. Therefore, the panel does not recommend the use of extended-infusion carbapenems with or without the addition of a second agent for the treatment of CRE when non-susceptibility to meropenem has been demonstrated.

Cefiderocol is also likely to be active against most CRE clinical isolates as it exhibits activity against Enterobacterales producing any of the 5 major carbapenemase enzymes [133]. However, the panel recommends cefiderocol as an alternative agent for infections caused by CRE other than metallo- β -lactamase-producing Enterobacterales (eg, NDM, VIM, IMP) (Question 5). Patients with CRE infections who have received medical care in countries with a relatively high prevalence of metallo- β -lactamase-producing CRE within the previous 12 months [134] or who have previously had a clinical or surveillance culture where metallo- β -lactamase-producing organisms were identified have a high likelihood of being infected with metallo- β -lactamase-producing Enterobacterales. For such patients (if carbapenemase results are not available),

preferred treatment options include the combination of ceftazidime-avibactam plus aztreonam, or cefiderocol as monotherapy (Question 5). However, if carbapenemase testing is available and is negative, monotherapy with ceftazidime-avibactam, meropenem-vaborbactam, or imipenem-cilastatin-relebactam are preferred treatment options. Tigecycline or eravacycline (as monotherapy) are alternative options for the treatment of CRE infections not involving the bloodstream or urinary tract (Question 7). Their activity is independent of the presence or type of carbapenemase.

Question 5: What Are the Preferred Antibiotics for the Treatment of Infections Outside of the Urinary Tract Caused by CRE if Carbapenemase Production is Present?

Recommendation: Meropenem-vaborbactam, ceftazidime-avibactam, and imipenem-cilastatin-relebactam are preferred treatment options for KPC-producing infections outside of the urinary tract. Ceftazidime-avibactam in combination with aztreonam, or cefiderocol as monotherapy, are preferred treatment options for NDM and other metallo- β -lactamase-producing infections. Ceftazidime-avibactam is the preferred treatment option for OXA-48-like-producing infections.

Rationale

Preferred agents for CRE infections differ based on the identification of specific carbapenemases [135]. Tigecycline or eravacycline, but not omadacycline, are alternative options for the treatment of CRE infections (Question 7). Their activity is independent of the presence or type of carbapenemase produced.

KPC Producers. For KPC-producing organisms, preferred agents include meropenem-vaborbactam, ceftazidime-avibactam, or imipenem-cilastatin-relebactam [109, 111–116, 136]. These agents are associated with improved clinical outcomes and reduced toxicity compared to other regimens commonly used to treat KPC-producing infections, which are often polymyxin-based [124–132, 136].

Comparative effectiveness studies between the preferred agents are limited and no clinical trials exist comparing the novel agents. An observational study compared the clinical outcomes of patients who received either meropenem-vaborbactam or ceftazidime-avibactam for at least 72 hours for the treatment of CRE infections [137]. Carbapenemase status was largely unavailable. Clinical cure and 30-day mortality between the 26 patients who received meropenem-vaborbactam and 105 patients who received ceftazidime-avibactam were similar at 69% and 62% and 12% and 19%, respectively. Of patients who experienced recurrent CRE infections, 0 of 3 patients receiving meropenem-vaborbactam, and 3 of 15 patients receiving ceftazidime-avibactam had subsequent CRE isolates that developed resistance to initial therapy. This study had a number of important limitations: likely selection bias due to its

observational nature, relatively small numbers of patients, heterogeneous sites of CRE infection, more than half of patients had polymicrobial infections, and more than half of patients received additional antibiotic therapy. These limitations notwithstanding, this study suggests that meropenem-vaborbactam and ceftazidime-avibactam are associated with similar clinical outcomes, although the emergence of resistance may be more common with ceftazidime-avibactam (**Question 6**). Therefore, the panel expresses a slight preference for the use of meropenem-vaborbactam over ceftazidime-avibactam for the treatment of KPC-producing organisms, but both are preferred options for this indication.

Limited clinical data are available for imipenem-cilastatin-relebactam compared with the other novel β -lactam- β -lactamase inhibitor agents. A clinical trial randomized patients with infections caused by gram-negative organisms not susceptible to imipenem receiving imipenem-cilastatin-relebactam versus imipenem-cilastatin and colistin [127]. Of patients with Enterobacterales infections, 40% (2 of 5 patients) and 100% (2 of 2 patients) experienced a favorable clinical response with imipenem-cilastatin-relebactam and imipenem-cilastatin in combination with colistin, respectively [127]. It is difficult to draw meaningful conclusions from these data given the small numbers. However, *in vitro* activity of imipenem-cilastatin-relebactam against CRE [118, 138–141], clinical experience with imipenem-cilastatin, and the stability of relebactam as a β -lactamase inhibitor [142] suggest imipenem-cilastatin-relebactam is likely to be effective for CRE infections if it tests susceptible. Studies comparing the clinical outcomes of imipenem-cilastatin-relebactam and ceftazidime-avibactam or meropenem-vaborbactam for CRE infections are not available. Although ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-cilastatin-relebactam are all recommended as preferred agents for the treatment of KPC-producing infections, the panel slightly favors meropenem-vaborbactam, followed by ceftazidime-avibactam, and then imipenem-cilastatin-relebactam, based on available data.

Cefiderocol is an alternative treatment option for KPC-producing Enterobacterales [133]. A clinical trial found that clinical cure occurred in 66% (19 of 29) and 45% (5 of 11) of CRE infected patients treated with cefiderocol versus alternative agents (mostly polymyxin-based regimens), respectively [105]. All-cause mortality was 23% (9 of 40) versus 21% (4 of 19) in patients with carbapenem-resistant *K. pneumoniae* or carbapenem-resistant *E. coli*, treated with cefiderocol versus alternative agents, respectively. When patients with concomitant *Acinetobacter* infection were excluded, all-cause mortality was 19% (6 of 31) versus 25% (4 of 16) in patients with *K. pneumoniae* or *E. coli* treated with cefiderocol versus alternative therapy, respectively. Although clinical investigations comparing the effectiveness of cefiderocol versus newer β -lactam- β -lactamase inhibitors for KPC-producing Enterobacterales infections are not available, available data do not suggest cefiderocol is associated

with suboptimal outcomes. However, the panel recommends cefiderocol as an alternative agent for treating KPC-producing pathogens as it prefers its activity be reserved for the treatment of metallo- β -lactamase-producing Enterobacterales (eg, NDM, VIM, IMP producers) or for select glucose non-fermenting gram-negative organisms [143].

NDM Producers. If Enterobacterales isolates produce NDMs (or any other metallo- β -lactamase), preferred antibiotic options include ceftazidime-avibactam plus aztreonam, or cefiderocol monotherapy [105, 144–149]. Ceftazidime-avibactam (monotherapy), meropenem-vaborbactam, and imipenem-cilastatin-relebactam are not effective against metallo- β -lactamase producing infections.

NDMs hydrolyze penicillins, cephalosporins, and carbapenems but not aztreonam. Although aztreonam is active against NDMs, it can be hydrolyzed by ESBLs, AmpC β -lactamases, or OXA-48-like carbapenemases, which are frequently co-produced by NDM-producing isolates. Avibactam generally remains effective against these latter β -lactamase enzymes. An observational study of 102 adults with bloodstream infections caused by metallo- β -lactamase-producing Enterobacterales compared the outcomes of 52 patients receiving ceftazidime-avibactam in combination with aztreonam versus 50 patients receiving a combination of other agents, primarily polymyxin or tigecycline-based therapy [149]. Thirty-day mortality was 19% for the ceftazidime-avibactam/aztreonam group and 44% for the alternate arm, highlighting the potential clinical benefit with the former. When the combination of ceftazidime-avibactam and aztreonam are administered to treat metallo- β -lactamase producing infections, it is recommended that they be administered simultaneously rather than sequentially [150].

Another preferred option for the treatment of NDM and other metallo- β -lactamase-producing Enterobacterales is cefiderocol. Surveillance data indicate that NDM-producing Enterobacterales isolates have a higher cefiderocol MIC₉₀ than isolates that produce serine β -lactamases, although this is not always associated with frank cefiderocol resistance [133, 151]. Among 151 international CRE isolates, cefiderocol was active against 98% of all isolates [133]. On closer inspection, cefiderocol was active against 100% of 75 KPC-producing Enterobacterales isolates, 100% of 32 OXA-48-like isolates, but only 58% of the 12 NDM-producing Enterobacterales isolates, using cefiderocol MICs of ≤ 4 mcg/mL as indicative of susceptibility [133]. Similar data on the percent of NDM-producing isolates susceptible to the combination of ceftazidime-avibactam and aztreonam are not available, in part because there is no Clinical and Laboratory Standards Institute (CLSI)-standardized approach to identifying *in vitro* activity of this antibiotic combination against bacterial isolates [15]. A clinical trial including patients with metallo- β -lactamase producing infections

(not limited to the Enterobacterales) found that clinical cure occurred in 75% (12 of 16) and 29% (2 of 7) of patients receiving ceftiderocol versus alternate therapy (primarily polymyxin-based therapy), respectively [105]. Clinical outcomes data comparing ceftazidime-avibactam in combination with aztreonam versus ceftiderocol are not available. The panel recommends both treatment options as preferred options for metallo- β -lactamase-producing Enterobacterales.

OXA-48-like Producers. If an OXA-48-like enzyme is identified, ceftazidime-avibactam is preferred [109, 110, 152], and ceftiderocol is an alternative option. Meropenem-vaborbactam and imipenem-cilastatin-relebactam have limited to no activity against CRE producing OXA-48-like enzymes [111–119]. Although OXA-48-like producing isolates are generally expected to test susceptible to ceftiderocol, clinical data on ceftiderocol treatment of infections by these organisms are limited.

Question 6: What Is the Likelihood of the Emergence of Resistance of CRE Isolates to the Newer β -Lactam Agents When Used to Treat CRE Infections?

Recommendation: The emergence of resistance is a concern with all of the novel β -lactams used to treat CRE infections, but the frequency appears to be the highest for ceftazidime-avibactam.

Rationale

As with most antibiotic agents, treatment with any of the newer β -lactam agents active against CRE (ie, ceftazidime-avibactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, or ceftiderocol) increases the likelihood that subsequent isolates causing infection will no longer be effectively treated with these agents. The emergence of resistance to ceftazidime-avibactam most commonly occurs because of mutations in the *bla*_{KPC} gene translating to amino acid changes in the KPC carbapenemase [153–169]. Changes in permeability and efflux are the primary drivers of the emergence of resistance to meropenem-vaborbactam [113, 162, 166, 170–176] and imipenem-cilastatin-relebactam [177, 178]. A number of diverse mechanisms of resistance to ceftiderocol have been described including mutations in the TonB-dependent iron transport system [179–182], amino acid changes in AmpC β -lactamases [183, 184], and increased NDM expression [185]. The reader is referred to review articles on this topic for a more complete understanding of the mechanisms of resistance to the novel β -lactams [143, 186, 187].

Estimates of the emergence of resistance after clinical exposure to ceftazidime-avibactam and meropenem-vaborbactam are approximately 20% [128, 132, 157, 188] and 3% [137, 176, 189], respectively. Most data are available for ceftazidime-avibactam, in part because it was the first of the novel β -lactam agents active against CRE to receive approval from the US Food and Drug Administration. Very limited data exist on the frequency of

emergence of resistance to imipenem-cilastatin-relebactam. Whether this is indicative of the successful properties of this combination or the result of limited use is not clear. Similarly, estimates of the frequency of the emergence of resistance to ceftiderocol since its clinical introduction are not yet available.

The panel recommends always repeating antibiotic susceptibility testing for the newer β -lactams when a patient previously infected with a CRE presents with a sepsis-like picture suggestive of a new or relapsed infection. Furthermore, if a patient was recently treated with ceftazidime-avibactam and presents with a sepsis-like condition, the panel suggests considering use of a different novel β -lactam agent at least until culture and susceptibility data are available. For example, if a patient with a KPC-producing bloodstream infection received a treatment course of ceftazidime-avibactam 1 month earlier and presents to medical care with symptoms suggestive of infection, consider administering an agent such as meropenem-vaborbactam until organism and susceptibility data are available.

Question 7: What Is the Role of Tetracycline Derivatives for the Treatment of Infections Caused by CRE?

Recommendation: Although β -lactam agents remain preferred treatment options for CRE infections, tigecycline and eravacycline are alternative options when β -lactam agents are either not active or unable to be tolerated. The tetracycline derivatives are not recommended as monotherapy for the treatment of CRE urinary tract infections or bloodstream infections.

Rationale

Tetracycline derivatives function independent of the presence or type of carbapenemase. More specifically, both carbapenemase-producing (eg, KPC, NDM, OXA-48-like carbapenemases) and non-carbapenemase-producing CRE may test susceptible to these agents [112, 190]. The tetracycline-derivative agents generally achieve rapid tissue distribution following administration, resulting in limited urine and serum concentrations [191]. Therefore, the panel recommends avoiding their use for urinary and bloodstream infections. Tigecycline or eravacycline can be considered as alternative options for intra-abdominal infections, skin and soft tissue infections, osteomyelitis, and respiratory infections when optimal dosing is used (Table 1).

Tigecycline has more published experience available for the treatment of CRE infections than eravacycline [192–195]. A meta-analysis of 15 randomized trials suggested that tigecycline monotherapy is associated with higher mortality than alternative regimens used for the treatment of pneumonia, not exclusively limited to pneumonia caused by the Enterobacterales [196]. Subsequent investigations have demonstrated that when high-dose tigecycline is prescribed (200 mg intravenously as a single dose followed 100 mg intravenously every 12 hours) mortality differences between tigecycline and

comparator agents may no longer be evident [197–199]. Thus, if tigecycline is prescribed for the treatment of CRE infections, the panel recommends that high-dosages be administered [200] (Table 1).

Eravacycline MICs are generally 2- to 4-fold lower than tigecycline MICs against CRE [201]. The clinical relevance of the MIC distributions between these agents is unclear because of differences in the pharmacokinetic/pharmacodynamic profile of tigecycline and eravacycline. Fewer than 5 patients with CRE infections were included in clinical trials that investigated the efficacy of eravacycline [192, 202], and post-marketing clinical reports describing its efficacy for the treatment of CRE infections are limited [203].

Limited clinical data are also available investigating the effectiveness of minocycline against CRE infections [204, 205], but data suggest a lower proportion of CRE isolates are likely to be susceptible to minocycline compared to tigecycline or eravacycline. The panel suggests using minocycline with caution for the treatment of CRE infections. Data evaluating the activity of omadacycline, a tetracycline-derivative with both an intravenous and oral formulation, against CRE suggests reduced potency relative to other tetracycline derivatives and an unfavorable pharmacokinetic and pharmacodynamic profile [50, 206–208]. The panel suggests avoiding the use of omadacycline for the treatment of CRE infections.

Question 8: What Is the Role of Polymyxins for the Treatment of Infections Caused by CRE?

Recommendation: Polymyxin B and colistin should be avoided for the treatment of infections caused by CRE. Colistin can be considered as an alternative agent for uncomplicated CRE cystitis.

Rationale

Observational and RCT data indicate increased mortality and excess nephrotoxicity associated with polymyxin-based regimens relative to comparator agents [124–132]. Concerns about the clinical effectiveness of polymyxins and accuracy of polymyxin susceptibility testing led the CLSI to eliminate a susceptible category for colistin and polymyxin B [15]. The panel recommends that these agents be avoided for the treatment of CRE infections, with the exception of colistin as an alternative agent against CRE cystitis. Polymyxin B should not be used as treatment for CRE cystitis, due to its predominantly nonrenal clearance [107].

Question 9: What Is the Role of Combination Antibiotic Therapy for the Treatment of Infections Caused by CRE?

Recommendation: Combination antibiotic therapy (ie, the use of a β -lactam agent in combination with an aminoglycoside, fluoroquinolone, or polymyxin) is not routinely recommended for the treatment of infections caused by CRE.

Rationale

Although empiric combination antibiotic therapy increases the likelihood that at least 1 active therapeutic agent for patients at risk for CRE infections is being administered, data do not indicate that continued combination therapy—once the β -lactam agent has demonstrated in vitro activity—offers any additional benefit [209]. Rather, the continued use of a second agent increases the likelihood of antibiotic-associated adverse events [209].

Observational data and clinical trials comparing ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-cilastatin-relebactam to combination regimens (eg, ceftazidime-avibactam versus meropenem and colistin) for the treatment of CRE infections have not shown the latter to improve clinical outcomes [124–132]. An observational study compared the clinical outcomes of 165 patients receiving ceftazidime-avibactam and 412 patients receiving ceftazidime-avibactam plus a second agent for the treatment of KPC-producing infections [210]. Thirty-day mortality was essentially identical at approximately 25% in both study arms.

Randomized trial data are not available comparing the novel β -lactam agents as monotherapy and as a component of combination therapy (eg, ceftazidime-avibactam versus ceftazidime-avibactam and amikacin). However, based on available outcomes data, clinical experience, and known toxicities associated with aminoglycosides, fluoroquinolones, and polymyxins, the panel does not routinely recommend combination therapy for CRE infections when susceptibility to a preferred β -lactam agent has been demonstrated.

PSEUDOMONAS AERUGINOSA WITH DIFFICULT-TO-TREAT RESISTANCE

The CDC reports that 32 600 cases of multidrug-resistant (MDR) *P. aeruginosa* infection occurred in patients hospitalized in the United States in 2017, resulting in 2700 deaths [1]. MDR *P. aeruginosa* is defined as *P. aeruginosa* not susceptible to at least 1 antibiotic in at least 3 antibiotic classes for which *P. aeruginosa* susceptibility is generally expected: penicillins, cephalosporins, fluoroquinolones, aminoglycosides, and carbapenems [211]. In 2018, the concept of “difficult-to-treat” resistance was proposed [3]. In this guidance document, DTR is defined as *P. aeruginosa* exhibiting non-susceptibility to all of the following: piperacillin-tazobactam, ceftazidime, cefepime, aztreonam, meropenem, imipenem-cilastatin, ciprofloxacin, and levofloxacin.

Multidrug-resistant *P. aeruginosa* or DTR-*P. aeruginosa* generally evolve as a result of an interplay of multiple complex resistance mechanisms, including decreased expression of outer membrane porins (OprD), hyperproduction of AmpC enzymes, upregulation of efflux pumps, and mutations in penicillin-binding protein targets [212, 213]. Carbapenemase production is a rare cause of carbapenem resistance in *P. aeruginosa* in

the United States but is identified in upward of 20% of carbapenem-resistant *P. aeruginosa* in other regions of the world [214–216]. Treatment recommendations for DTR-*P. aeruginosa* infections listed below assume that in vitro activity of preferred and alternative antibiotics has been demonstrated.

Question 1: What Are Preferred Antibiotics for the Treatment of Infections Caused by MDR *P. aeruginosa*?

Recommendation: When *P. aeruginosa* isolates test susceptible to traditional non-carbapenem β -lactam agents (ie, piperacillin-tazobactam, ceftazidime, cefepime, aztreonam), they are preferred over carbapenem therapy. For infections caused by *P. aeruginosa* isolates not susceptible to any carbapenem agents but susceptible to traditional β -lactams, the administration of a traditional agent as high-dose extended-infusion therapy is suggested, after antibiotic susceptibility testing results are confirmed. For patients with moderate to severe disease or poor source control with *P. aeruginosa* isolates resistant to carbapenems but susceptible to traditional β -lactams, use of a novel β -lactam agent that tests susceptible (eg, ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-cilastatin-relebactam) is also a reasonable treatment option.

Rationale

In general, when a *P. aeruginosa* isolate tests susceptible to multiple traditional β -lactam agents (ie, piperacillin-tazobactam, ceftazidime, cefepime, aztreonam) or fluoroquinolones (ie, ciprofloxacin, levofloxacin), the panel prefers these agents be prescribed over carbapenem therapy in an attempt to preserve the activity of carbapenems for future, increasingly drug-resistant infections.

P. aeruginosa isolates not susceptible to a carbapenem agent (eg, meropenem or imipenem-cilastatin MICs ≥ 4 mcg/mL) but susceptible to other traditional non-carbapenem β -lactam agents (eg, piperacillin-tazobactam MIC $\leq 16/4$ mcg/mL, ceftazidime ≤ 8 mcg/mL, cefepime ≤ 8 mcg/mL, or aztreonam ≤ 8 mcg/mL) [15] constitute approximately 20–60% of carbapenem-resistant *P. aeruginosa* isolates [217–223]. This phenotype is generally due to lack of or limited production of OprD, which normally facilitates entry of carbapenem agents into bacteria [219–222]. Comparative effectiveness studies to guide treatment decisions for infections caused by *P. aeruginosa* resistant to carbapenems but susceptible to other traditional non-carbapenem β -lactams are not available. When confronted with these scenarios, the panel suggests repeating susceptibility testing to confirm antibiotic MICs. If the isolate remains susceptible to a traditional non-carbapenem β -lactam (eg, cefepime) on repeat testing, the panel's preferred approach is to administer the non-carbapenem agent as high-dose extended-infusion therapy (eg, cefepime 2 g IV every 8 hours, infused over 3 hours) (Table 1).

An alternative approach is to administer a novel β -lactam agent (eg, ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-cilastatin-relebactam), selecting an agent that tests susceptible. This approach is considered an alternative option to preserve the effectiveness of novel β -lactams for future, increasingly antibiotic-resistant infections. However, for patients with moderate to severe infection or with poor source control, use of a novel β -lactam for MDR *P. aeruginosa* infections resistant to carbapenems but susceptible to non-carbapenem β -lactams is a reasonable consideration. Regardless of the antibiotic agent administered, patients infected with *P. aeruginosa* should be closely monitored to ensure clinical improvement as *P. aeruginosa* exhibits an impressive capacity to acquire additional resistance mechanisms while exposed to antibiotic therapy.

Question 2: What Are Preferred Antibiotics for the Treatment of Uncomplicated Cystitis Caused by DTR-*P. aeruginosa*?

Recommendation: Ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-cilastatin-relebactam, cefiderocol, or a single-dose of an aminoglycoside are the preferred treatment options for uncomplicated cystitis caused by DTR-*P. aeruginosa*.

Rationale

Ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-cilastatin-relebactam, and cefiderocol are preferred treatment options for uncomplicated DTR-*P. aeruginosa* cystitis, based on RCTs showing non-inferiority of these agents to common comparator agents for the treatment of UTIs [101, 103–105, 224]. Data are insufficient to favor 1 of these agents over the others for the treatment of uncomplicated cystitis, and available trials generally do not include patients infected by pathogens with DTR phenotypes. Additional information comparing these agents is described in **Question 4**.

A single dose of an aminoglycoside is also a preferred treatment option. Aminoglycosides are nearly exclusively eliminated by the renal route in their active form. A single intravenous dose is generally effective for uncomplicated cystitis, with minimal toxicity, but robust trial data are lacking [28]. Plazomicin is unlikely to provide any incremental benefit against DTR-*P. aeruginosa* if resistance to all other aminoglycosides is demonstrated [225].

Colistin, but not polymyxin B, is an alternate consideration for treating DTR-*P. aeruginosa* cystitis as it converts to its active form in the urinary tract [106]. Clinicians should remain cognizant of the associated risk of nephrotoxicity. The panel does not recommend the use of oral fosfomycin for DTR-*P. aeruginosa* cystitis as it is associated with a high likelihood of clinical failure [18, 226]. This is in part due to the presence of the *fosA* gene, which is intrinsic to *P. aeruginosa* [29].

Question 3: What Are Preferred Antibiotics for the Treatment of Pyelonephritis and Complicated Urinary Tract Infections Caused by DTR-*P. aeruginosa*?

Recommendation: Ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-cilastatin-relebactam, and ceftiderocol are the preferred treatment options for pyelonephritis and cUTI caused by DTR-*P. aeruginosa*.

Rationale

Ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-cilastatin-relebactam, and ceftiderocol are preferred treatment options for DTR-*P. aeruginosa* pyelonephritis and cUTI, based on RCTs showing non-inferiority of these agents to common comparator agents [101, 103–105, 224]. Data are insufficient to favor 1 of these agents over the others for the treatment of pyelonephritis and cUTI, and available trials generally do not include patients infected by pathogens with DTR phenotypes. Additional information comparing these agents is described in **Question 4**.

In patients in whom the potential for nephrotoxicity is deemed acceptable, once-daily aminoglycosides are an alternative option [38]. Plazomicin is unlikely to provide any incremental benefit against DTR-*P. aeruginosa* if resistance to all other aminoglycosides is demonstrated [225].

Question 4: What Are Preferred Antibiotics for the Treatment of Infections Outside of the Urinary Tract Caused by DTR-*P. aeruginosa*?

Recommendation: Ceftolozane-tazobactam, ceftazidime-avibactam, and imipenem-cilastatin-relebactam, as monotherapy, are preferred options for the treatment of infections outside of the urinary tract caused by DTR-*P. aeruginosa*.

Rationale

Ceftolozane-tazobactam, ceftazidime-avibactam, and imipenem-cilastatin-relebactam, as monotherapy, are preferred options for the treatment of infections outside of the urinary tract, based on in vitro activity [139, 141, 177, 227–268], observational studies [269], and clinical trial data [101, 127, 270–276]. The vast majority of patients in clinical trials receiving the novel β -lactam- β -lactamase inhibitors were not infected with DTR-*P. aeruginosa*.

Summarizing international surveillance data, ceftolozane-tazobactam [227, 229, 230, 232–242, 253], ceftazidime-avibactam [228, 241–253], and imipenem-cilastatin-relebactam [139, 141, 177, 253–268] are active against approximately 76%, 74%, and 69% of carbapenem-resistant *P. aeruginosa* isolates, respectively, with lower percent susceptibilities exhibited by isolates from patients with cystic fibrosis [277, 278]. Available surveillance data generally represent time periods before the novel agents were used clinically and likely overestimate susceptibility percentages observed in clinical practice. Ceftolozane does not rely on an inhibitor to restore susceptibility to an otherwise inactive drug (ie, ceftolozane has independent activity against DTR-*P. aeruginosa*), which may explain

its slightly higher likelihood of activity against DTR-*P. aeruginosa* compared to other novel β -lactam- β -lactamase inhibitors. Neither ceftazidime nor imipenem is active against DTR-*P. aeruginosa*. Avibactam and relebactam expand activity of these agents mainly through inhibition of AmpC, but other complex resistance mechanisms are unlikely to be impacted. Regional differences in susceptibility estimates across the newer agents likely exist. The panel recommends always obtaining antibiotic susceptibility testing results for DTR-*P. aeruginosa* infections to guide treatment decisions.

Clinical trials comparing effectiveness across the newer agents are not available, but observational data and subgroup analysis from clinical trial data provide insights into the effectiveness of the newer β -lactam agents compared to traditional anti-pseudomonal regimens. An observational study including 200 patients with MDR *P. aeruginosa* compared the outcomes of patients receiving ceftolozane-tazobactam versus polymyxin or aminoglycoside-based therapy [269]. Favorable clinical outcomes were observed in 81% of patients receiving ceftolozane-tazobactam versus 61% of patients receiving polymyxin- or aminoglycoside-based therapy; this difference achieved statistical significance. An RCT including 24 patients infected with imipenem-non-susceptible *P. aeruginosa* identified a favorable clinical response in 81% of patients receiving imipenem-cilastatin-relebactam compared to 63% receiving imipenem-cilastatin in combination with colistin [127]. Although not achieving statistical significance, potentially due to the small sample size, the numerical differences suggest improved outcomes with use of imipenem-cilastatin-relebactam over more traditional regimens. Rigorous data investigating the activity of ceftazidime-avibactam against comparators are lacking. However, pooled data from 5 RCTs explored differences in clinical responses for patients with MDR *P. aeruginosa* infections receiving ceftazidime-avibactam versus more traditional regimens with a favorable clinical response observed in 57% (32 of 56 patients) versus 54% (21 of 39) of patients in the 2 treatment arms, respectively [279]. An important limitation to these data were that only 66% of isolates were susceptible to ceftazidime-avibactam making interpretation of the results challenging [279].

Ceftiderocol is recommended as an alternative treatment option for DTR-*P. aeruginosa* infections outside of the urine. Ceftiderocol is a synthetic conjugate composed of a cephalosporin moiety and a catechol-type siderophore, which binds to iron and facilitates bacterial cell entry using active iron transporters [143]. Once inside the periplasmic space, the cephalosporin moiety dissociates from iron and binds primarily to penicillin-binding protein 3 to inhibit bacterial cell wall synthesis [280]. Combining data from 1500 carbapenem-non-susceptible *P. aeruginosa* isolates in surveillance studies, over 97% of isolates exhibited susceptibility to ceftiderocol (ie, MICs ≤ 4 mcg/mL) [133, 281–286]. Similar to the novel β -lactam- β -lactamase

inhibitors, percent susceptibility to ceftiderocol is likely to be reduced after widespread use of this agent.

An RCT compared the outcomes of patients with infections due to carbapenem-resistant organisms treated with ceftiderocol versus best available therapy, which was largely polymyxin-based therapy [105]. The trial included 22 unique patients with 29 CR-*P. aeruginosa* infections, including 6 patients with UTIs, 17 patients with pneumonia, and 6 patients with bloodstream infections [287]. Mortality at the end of therapy was 18% in both the ceftiderocol and best available therapy arms for patients infected with *P. aeruginosa*. This trial suggests that ceftiderocol performs as well as agents that were the mainstay of treatment against DTR-*P. aeruginosa* in the past such as combinations of extended-infusion meropenem, polymyxins, and aminoglycosides but may not be associated with improved outcomes, as has been observed with some of the newer β -lactam- β -lactamase inhibitors [127, 269]. Despite the high likelihood of ceftiderocol activity against DTR-*P. aeruginosa*, the panel recommends ceftiderocol as an alternative option when inactivity, intolerance, or unavailability precludes the use of the newer β -lactam- β -lactamase inhibitors.

Question 5: What Is the Likelihood of the Emergence of Resistance of DTR-*P. aeruginosa* Isolates to the Newer β -Lactam Agents When Used to Treat DTR-*P. aeruginosa* Infections?

Recommendation: The emergence of resistance is a concern with all of the novel β -lactams used to treat DTR-*P. aeruginosa* infections, but the frequency appears to be the highest for ceftolozane-tazobactam and ceftazidime-avibactam.

Rationale

As with most antibiotic agents, treatment of DTR-*P. aeruginosa* with any of the newer β -lactam agents (ie, ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-cilastatin-relebactam, or ceftiderocol) increases the likelihood that subsequent infections will no longer be effectively treated with these agents. The emergence of resistance to ceftolozane-tazobactam most commonly occurs because of amino acid substitutions, insertions, or deletions in *Pseudomonas*-derived cephalosporinase (PDC), the chromosomally encoded class C β -lactamase of *P. aeruginosa*, commonly referred to as “the pseudomonal AmpC” [8, 231, 288–299]. These alterations occur most commonly in or adjacent to a particular region of the PDC known as the “omega loop.” Similarly, acquired resistance of *P. aeruginosa* to ceftazidime-avibactam is most frequently the result of alterations in PDCs [288, 290, 291, 293, 296, 298–301].

Mechanisms contributing to *P. aeruginosa* resistance to imipenem-cilastatin-relebactam are less clear and may be related to increased production of PDCs in combination with loss of OprD [177, 302]. A number of diverse mechanisms of *P. aeruginosa* resistance to ceftiderocol have been described including mutations in the TonB-dependent iron transport system [179–181, 303] or amino acid changes in the AmpC β -lactamases

[303, 304]. The reader is referred to comprehensive review articles on this topic for a more complete understanding of the mechanisms of resistance to the novel β -lactams [143, 186, 187].

Based on available data thus far, the emergence of resistance of *P. aeruginosa* to novel β -lactams appears most concerning for ceftolozane-tazobactam and ceftazidime-avibactam. Cross-resistance between these agents is high because of similar mechanisms of resistance. In a cohort of 28 patients with DTR-*P. aeruginosa* infections treated with ceftolozane-tazobactam, 50% of patients were infected with subsequent DTR-*P. aeruginosa* isolates no longer susceptible to ceftolozane-tazobactam [299]. Remarkably, over 80% of patients with index isolates susceptible to ceftazidime-avibactam had subsequent isolates with high-level resistance to ceftazidime-avibactam after ceftolozane-tazobactam exposure, and in the absence of ceftazidime-avibactam exposure. Another cohort study including 23 patients with index and subsequent *P. aeruginosa* isolates after ceftolozane-tazobactam described a similar experience [298]. Treatment-emergent mutations in *ampC* were identified in 79% of paired isolates. Limited data on the frequency of emergence of resistance to imipenem-cilastatin-relebactam exist. Whether this is indicative of the successful properties of this combination or the result of its limited clinical use is not clear. Similarly, estimates of the frequency of the emergence of resistance of *P. aeruginosa* to ceftiderocol since its clinical introduction are not yet available but in a clinical trial, 3 of 12 carbapenem-resistant isolates had at least 4-fold increases in ceftiderocol MICs (though not necessarily frank resistance) after exposure to this agent [105].

The panel recommends always repeating antibiotic susceptibility testing for the newer β -lactams when a patient previously infected with a DTR-*P. aeruginosa* presents with a sepsis-like picture suggestive of a new or relapsed infection. Furthermore, if a patient was recently treated with ceftolozane-tazobactam or ceftazidime-avibactam and presents to medical care with symptoms of infection, the panel suggests considering use of a different novel β -lactam agent at least until culture and susceptibility data are available.

Question 6: What Is the Role of Combination Antibiotic Therapy for the Treatment of Infections Caused by DTR-*P. aeruginosa*?

Recommendation: Combination antibiotic therapy is not routinely recommended for infections caused by DTR-*P. aeruginosa* if in vitro susceptibility to a first-line antibiotic (ie, ceftolozane-tazobactam, ceftazidime-avibactam, or imipenem-cilastatin-relebactam) has been confirmed.

Rationale

Although empiric combination antibiotic therapy (eg, the addition of an aminoglycoside to a β -lactam agent) to broaden the likelihood of at least 1 active therapeutic agent for patients at risk for DTR-*P. aeruginosa* infections is reasonable, data do

not indicate that continued combination therapy—once the β -lactam agent has demonstrated in vitro activity—offers any additional benefit over monotherapy with the β -lactam [209]. Rather, the continued use of a second agent increases the likelihood of antibiotic-associated adverse events [209].

Observational data and clinical trials that have compared ceftolozane-tazobactam and imipenem-cilastatin-relebactam, usually given as monotherapy, to combination regimens for drug-resistant *P. aeruginosa* infections have not shown the latter to have added value [127, 269]. Randomized trial data comparing ceftolozane-tazobactam, ceftazidime-avibactam, or imipenem-cilastatin-relebactam as monotherapy and as a component of combination therapy are not available (eg, ceftazidime-avibactam versus ceftazidime-avibactam and amikacin). Based on existing outcomes data, clinical experience, and known toxicities associated with aminoglycosides and polymyxins, the panel does not recommend that combination therapy be routinely administered for DTR-*P. aeruginosa* infections when susceptibility to a preferred β -lactam agent has been demonstrated.

If no preferred agent demonstrates activity against DTR-*P. aeruginosa*, an aminoglycoside (if susceptibility is demonstrated) can be considered in combination with either ceftolozane-tazobactam, ceftazidime-avibactam, or imipenem-cilastatin-relebactam, preferentially selecting the β -lactam- β -lactamase inhibitor agent for which the MIC is closest to its susceptibility breakpoint. For example, if ceftolozane-tazobactam and ceftazidime-avibactam MICs against a DTR-*P. aeruginosa* isolate are both $>128/4$ mcg/mL (highly resistant) and the imipenem-cilastatin-relebactam MIC is $4/4$ mcg/mL (intermediate category), imipenem-cilastatin-relebactam in combination with an active aminoglycoside is favored. Data are lacking demonstrating a benefit to this approach, and it should be considered as a last resort. Similarly, data are lacking whether this approach will yield more favorable clinical outcomes compared to cefiderocol, either as monotherapy or combination therapy. This approach is suggested as it may increase the likelihood that at least 1 active agent is being included in the treatment regimen.

If no aminoglycoside demonstrates in vitro activity, polymyxin B can be considered in combination with the β -lactam- β -lactamase inhibitor. Polymyxin B is preferred over colistin for non-urinary tract infections because (1) it is not administered as a prodrug and therefore can achieve more reliable plasma concentrations than colistin, and (2) it has a reduced risk of nephrotoxicity, although limitations across studies preclude accurate determination of the differential risk of nephrotoxicity [305–310].

Question 7: What Is the Role of Nebulized Antibiotics for the Treatment of Respiratory Infections Caused by DTR-*P. aeruginosa*?

Recommendation: The panel does not recommend the routine addition of nebulized antibiotics for the treatment of respiratory infections caused by DTR-*P. aeruginosa*.

Rationale

There have been conflicting findings for the clinical effectiveness of nebulized antibiotics for the treatment of Gram-negative pneumonia in observational studies [311–338]. Three RCTs compared the outcomes of patients with gram-negative ventilator-associated pneumonia comparing nebulized antibiotics versus placebo. All 3 trials allowed for the use of systemic antibiotics, at the discretion of the treating clinician. In brief, 1 trial compared the outcomes of 100 adults with pneumonia (34% caused by *P. aeruginosa*) treated with nebulized colistin versus placebo [339]; a second trial compared the outcomes of 142 adults with pneumonia (22% caused by *P. aeruginosa*) treated with nebulized amikacin/fosfomycin versus placebo [340]; and the third trial compared the outcomes of 508 adults with pneumonia (32% caused by *P. aeruginosa*) treated with nebulized amikacin versus placebo [341]. None of the 3 clinical trials demonstrated improved clinical outcomes or a survival benefit with the use of nebulized antibiotics compared with placebo for the treatment of ventilator-associated pneumonia, including in subgroup analyses of drug-resistant pathogens [339–341].

Reasons for the lack of clinical benefit in these trials are unclear. In a pharmacokinetic-pharmacodynamic modeling study, aerosolized delivery of the prodrug of colistin to critically ill patients achieved high active drug levels in epithelial lining fluid of the lungs [342]. However, it is likely that nebulized antibiotics do not achieve sufficient penetration and/or distribution throughout lung tissue to exert significant bactericidal activity [343], likely due in part to the use of parenteral formulations not specifically designed for inhalation in suboptimal delivery devices such as jet nebulizers [344, 345]. Professional societies have expressed conflicting views regarding the role of nebulized antibiotics as adjunctive therapy to intravenous antibiotics [346–348]. The panel recommends against the use of nebulized antibiotics as adjunctive therapy for DTR-*P. aeruginosa* pneumonia due to the lack of benefit observed in clinical trials, concerns regarding unequal distribution in infected lungs, and concerns for respiratory complications such as bronchoconstriction in 10–20% of patients receiving aerosolized antibiotics [349].

CONCLUSIONS

The field of AMR is dynamic and rapidly evolving, and the treatment of antimicrobial-resistant infections will continue to challenge clinicians. As newer antibiotics against resistant pathogens are incorporated into clinical practice, we are learning more about their effectiveness and propensity to resistance. This treatment guidance focusing on ESBL-E, CRE, and DTR-*P. aeruginosa* will be updated annually and is available at: <https://www.idsociety.org/practice-guideline/amr-guidance/>. A second AMR treatment guidance focusing on the treatment

of infections caused by AmpC-producing Enterobacterales, carbapenem-resistant *Acinetobacter baumannii*, and *Stenotrophomonas maltophilia* infections is available at: <https://www.idsociety.org/practice-guideline/amr-guidance-2.0/>.

Notes

Acknowledgments. The authors express their sincere gratitude to the Infectious Diseases Society of America (IDSA) for organizing the development of this treatment guidance.

Potential conflicts of interest. The following list is a reflection of what has been reported to IDSA. To provide thorough transparency, IDSA requires full disclosure of all relationships, regardless of relevancy to the guidance topic. Evaluation of such relationships as potential conflicts of interest is determined by a review process which includes assessment by the Board of Directors liaison to the Standards and Practice Guidelines Committee and, if necessary, the Conflicts of Interest and Ethics Committee. The assessment of disclosed relationships for possible conflicts of interests is based on the relative weight of the financial relationship (ie, monetary amount) and the relevance of the relationship (ie, the degree to which an association might reasonably be interpreted by an independent observer as related to the topic or recommendation of consideration). Readers of this guidance should be mindful of this when the list of disclosures is reviewed. P. D. T. has nothing to disclose and does not receive any funding from any commercial groups. S. L. A. serves as advisor to Shionogi and Entasis Therapeutics; served on the advisory panel for Merck, Paratek, Medicines Company, Zavante, Shionogi, Sempra, and Theravance; and received research funding paid from Melinta and Merck. R. A. B. receives research funding from the National Institute of Allergy and Infectious Diseases, Veterans Health Administration, Shionogi, VenatoRx, Merck, Allegra, Wockhardt, Shionogi, AstraZeneca, Harrington Foundation, and Entasis; received research funding from Tetrphase and Steris; and served on the editorial boards for *Antimicrobial Agents and Chemotherapy*, *mBio*, and the Veterans Affairs Society for Prevention of Infectious Diseases. A. J. M. serves as a consultant/advisor for Merck, Shionogi, Qpex Biopharma, Accelerate Diagnostics, and VenatoRX; received research grants from the CDC and Wallace H. Coulter Endowment; and served as an advisor for Rempex and Antimicrobial Resistance Services. D. v. D. serves as member of the advisory group for Qpex Biopharma, Shionogi, and Merck; receives honoraria from Shionogi and Pfizer; receives other remuneration from the British Society for Antimicrobial Chemotherapy; receives research grants from Shionogi; served as an advisory board member for Entasis, Roche, Allergan, Utility, and Achaogen; served as non-promotional speaker for Entasis and Pfizer; received research funding from the National Institutes of Health and Merck; serves as editor-in-chief for *JAC-Antimicrobial Resistance*; and is on the program committee for the European Society of Clinical Microbiology and Infectious Diseases. C. J. C. served on the advisory board for Merck, Qpex Biopharma, and Shionogi; serves as an advisory Board member for Astellas, Cidara, and Scynexis; serves as a consultant for Needham & Associates; and receives research funding from Astellas and Merck. All other authors report no potential conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

- Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States 2019. 2019. Available at: <https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf>.
- Sears CL, File TM, Alexander BD, et al. Charting the path forward: development, goals and initiatives of the 2019 infectious diseases Society of America strategic plan. *Clin Infect Dis* 2019; 69:e1–7.
- Kadri SS, Adjemian J, Lai YL, et al. Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. *Clin Infect Dis* 2018; 67: 1803–14.
- Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clin Infect Dis* 2011; 52: e103–20.
- Heil EL, Bork JT, Abbo LM, et al. Optimizing the management of uncomplicated gram-negative bloodstream infections: consensus guidance using a modified Delphi process. *Open Forum Infect Dis* 2021; 8:ofab434.
- Jernigan JA, Hatfield KM, Wolford H, et al. Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012–2017. *N Engl J Med* 2020; 382:1309–19.
- Tamma PD, Sharara SL, Pana ZD, et al. Molecular epidemiology of ceftriaxone non-susceptible enterobacterales isolates in an academic medical center in the United States. *Open Forum Infect Dis* 2019; 6:ofz353.
- Haidar G, Philips NJ, Shields RK, et al. Ceftolozane-tazobactam for the treatment of multidrug-resistant *Pseudomonas aeruginosa* infections: clinical effectiveness and evolution of resistance. *Clin Infect Dis* 2017; 65:110–20.
- Tamma PD, Smith TT, Adebayo A, et al. Prevalence of *bla*_{CTX-M} genes in gram-negative bloodstream isolates across 66 hospitals in the United States. *J Clin Microbiol* 2021; 59: e00127-21.
- Bush K, Bradford PA. Epidemiology of β -lactamase-producing pathogens. *Clin Microbiol Rev* 2020; 33:e00047-19.
- Bush K, Jacoby GA. Updated functional classification of β -lactamases. *Antimicrob Agents Chemother* 2010; 54:969–76.
- Castanheira M, Farrell SE, Krause KM, Jones RN, Sader HS. Contemporary diversity of β -lactamases among *Enterobacteriaceae* in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent beta-lactamase groups. *Antimicrob Agents Chemother* 2014; 58: 833–8.
- Castanheira M, Simner PJ, Bradford PA. Extended-spectrum β -lactamases: an update on their characteristics, epidemiology and detection. *JAC Antimicrob Resist* 2021; 3:dlab092.
- Roberts FJ, Kohner PC, Patel R. Unreliable extended-spectrum β -lactamase detection in the presence of plasmid-mediated AmpC in *Escherichia coli* clinical isolates. *J Clin Microbiol* 2009; 47:358–61.
- Clinical and Laboratory Standards Institute. M100: performance standards for antimicrobial susceptibility testing. 31st ed. Wayne, PA: Clinical and Laboratory Standards Institute, 2021.
- Tamma PD, Humphries RM. PRO: testing for ESBL production is necessary for ceftriaxone-non-susceptible Enterobacterales: perfect should not be the enemy of progress. *JAC Antimicrob Resist* 2021; 3:dlab019.
- Mathers AJ, Lewis JS 2nd. CON: testing for ESBL production is unnecessary for ceftriaxone-resistant Enterobacterales. *JAC Antimicrob Resist* 2021; 3:dlab020.
- Huttner A, Kowalczyk A, Turjeman A, et al. Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: a randomized clinical trial. *JAMA* 2018; 319:1781–9.
- Gupta K, Hooton TM, Roberts PL, Stamm WE. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. *Arch Intern Med* 2007; 167:2207–12.
- Hooton TM, Scholes D, Gupta K, Stapleton AE, Roberts PL, Stamm WE. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. *JAMA* 2005; 293:949–55.
- Hooton TM, Roberts PL, Stapleton AE. Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. *JAMA* 2012; 307:583–9.
- Tanne JH. FDA adds 'black box' warning label to fluoroquinolone antibiotics. *BMJ* 2008; 337:a816.
- Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated *Clostridium difficile* infection. *Antimicrob Agents Chemother* 2013; 57:2326–32.
- Kazakova SV, Baggs J, McDonald LC, et al. Association between antibiotic use and hospital-onset clostridioides difficile infection in US acute care hospitals, 2006–2012: an ecologic analysis. *Clin Infect Dis* 2020; 70:11–8.
- Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for *Clostridium difficile*-associated diarrhea: a cohort study during an epidemic in Quebec. *Clin Infect Dis* 2005; 41:1254–60.
- Rodríguez-Baño J, Navarro MD, Retamar P, Picon E, Pascual A. Extended-spectrum beta-lactamases-red espanola de investigacion en patologia infecciosa/Grupo de Estudio de Infeccion Hospitalaria G. β -Lactam/ β -lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β -lactamase-producing *Escherichia coli*: a post hoc analysis of prospective cohorts. *Clin Infect Dis* 2012; 54:167–74.
- Beytur A, Yakupogullari Y, Oguz F, Otlu B, Kaysadu H. Oral amoxicillin-clavulanic acid treatment in urinary tract infections caused by extended-

- spectrum beta-lactamase-producing organisms. *Jundishapur J Microbiol* **2015**; 8:e13792.
28. Goodlet KJ, Benhalima FZ, Nailor MD. A systematic review of single-dose aminoglycoside therapy for urinary tract infection: is it time to resurrect an old strategy? *Antimicrob Agents Chemother* **2018**; 63:e02165-18.
 29. Ito R, Mustapha MM, Tomich AD, et al. Widespread fosfomycin resistance in gram-negative bacteria attributable to the chromosomal fosA gene. *mBio* **2017**; 8:e00749-17.
 30. Elliott ZS, Barry KE, Cox HL, et al. The role of fosA in challenges with fosfomycin susceptibility testing of multispecies *Klebsiella pneumoniae* carbapenemase-producing clinical isolates. *J Clin Microbiol* **2019**; 57:e00634-19.
 31. Mukerji AC, Sharma MM, Taneja OP, Saxena SN, Bhatnagar RK, Ghosh-Ray B. A clinical trial of alpha-6-deoxyoxytetracycline (doxycycline) in the treatment of urinary tract infections. *Chemotherapy* **1969**; 14:77-85.
 32. Musher DM, Minuth JN, Thorsteinsson SB, Holmes T. Effectiveness of achievable urinary concentrations of tetracyclines against 'tetracycline-resistant' pathogenic bacteria. *J Infect Dis* **1975**; 131:S40-4.
 33. Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylicylines. *J Antimicrob Chemother* **2006**; 58:256-65.
 34. Harris PNA, Tambyah PA, Lye DC, et al. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with *E coli* or *Klebsiella pneumoniae* bloodstream infection and ceftriaxone resistance: a randomized clinical trial. *JAMA* **2018**; 320:984-94.
 35. Sandberg T, Skoog G, Hermansson AB, et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. *Lancet* **2012**; 380:484-90.
 36. Ren H, Li X, Ni ZH, et al. Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial. *Int Urol Nephrol* **2017**; 49:499-507.
 37. Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. *JAMA* **2000**; 283:1583-90.
 38. Elbaz M, Zadka H, Weiss-Meilik A, Ben-Ami R. Effectiveness and safety of an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis. *J Antimicrob Chemother* **2020**; 75:2307-13.
 39. Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. Once-daily plazomicin for complicated urinary tract infections. *N Engl J Med* **2019**; 380:729-40.
 40. Procter and Gamble Pharmaceuticals, Inc. MACROBID - nitrofurantoin monohydrate and nitrofurantoin, macrocrystalline capsule [Package Insert]. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2009/020064s0191bl.pdf. Accessed 5 August 2020.
 41. U.S. Food and Drug Administration. MONUROL (fosfomycin tromethamine) SACHET [Package Insert]. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2008/050717s0051bl.pdf. Accessed 5 August 2020.
 42. Karaiskos I, Galani L, Sakka V, et al. Oral fosfomycin for the treatment of chronic bacterial prostatitis. *J Antimicrob Chemother* **2019**; 74:1430-7.
 43. Grayson ML, Macesic N, Trevillyan J, et al. Fosfomycin for treatment of prostatitis: new tricks for old dogs. *Clin Infect Dis* **2015**; 61:1141-3.
 44. Gardiner BJ, Mahony AA, Ellis AG, et al. Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis? *Clin Infect Dis* **2014**; 58:e101-5.
 45. Henderson A, Paterson DL, Chatfield MD, et al. Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO study. *Clin Infect Dis* **2021**; 73:e3842-50.
 46. Tamma PD, Conley AT, Cosgrove SE, et al. Association of 30-day mortality with oral step-down vs continued intravenous therapy in patients hospitalized with *Enterobacteriaceae* bacteremia. *JAMA Intern Med* **2019**; 179:316-23.
 47. Punjabi C, Tien V, Meng L, Deresinski S, Holubar M. Oral fluoroquinolone or trimethoprim-sulfamethoxazole vs. beta-lactams as step-down therapy for *Enterobacteriaceae* bacteremia: systematic review and meta-analysis. *Open Forum Infect Dis* **2019**; 6:ofz364.
 48. GlaxoSmithKline. AUGMENTIN® (amoxicillin/clavulanate potassium): Powder for Oral Suspension and Chewable Tablets [Package Insert]. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050575s037550597s044050725s025050726s0191bl.pdf. Accessed 14 September 2021.
 49. Iregui A, Landman D, Quale J. Activity of omadacycline and other tetracyclines against contemporary gram-negative pathogens from New York city hospitals. *Microb Drug Resist* **2021**; 27:190-5.
 50. Noel AR, Attwood M, Bowker KE, MacGowan AP. In vitro pharmacodynamics of omadacycline against *Escherichia coli* and *Acinetobacter baumannii*. *J Antimicrob Chemother* **2021**; 76:667-70.
 51. Bush K, Macalintal C, Rasmussen BA, Lee VJ, Yang Y. Kinetic interactions of tazobactam with beta-lactamases from all major structural classes. *Antimicrob Agents Chemother* **1993**; 37:851-8.
 52. Bitterman R, Paul M, Leibovici L, Mussini C. PipEracillin tazobactam versus mERoPENem for treatment of bloodstream infections caused by cephalosporin-resistant *Enterobacteriaceae* (PETERPEN). Available at: <https://clinicaltrials.gov/ct2/show/NCT03671967>. Accessed 16 September 2021.
 53. Sharara SL, Amoah J, Pana ZD, Simner PJ, Cosgrove SE, Tamma PD. Is piperacillin-tazobactam effective for the treatment of pyelonephritis caused by extended-spectrum beta-lactamase-producing organisms? *Clin Infect Dis* **2020**; 71:e331-7.
 54. Dizbay M, Özger HS, Karaşahin O, Karaşahin EF. Treatment efficacy and super-infection rates in complicated urinary tract infections treated with ertapenem or piperacillin tazobactam. *Turk J Med Sci* **2016**; 46:1760-4.
 55. Yoon YK, Kim JH, Sohn JW, Yang KS, Kim MJ. Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum beta-lactamase-producing *Escherichia coli*. *Int J Antimicrob Agents* **2017**; 49:410-5.
 56. Seo YB, Lee J, Kim YK, et al. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing *Escherichia coli*. *BMC Infect Dis* **2017**; 17:404.
 57. Gutiérrez-Gutiérrez B, Perez-Galera S, Salamanca E, et al. A multinational, preregistered cohort study of beta-lactam/beta-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-beta-lactamase-producing *Enterobacteriaceae*. *Antimicrob Agents Chemother* **2016**; 60:4159-69.
 58. Harris PN, Yin M, Jureen R, et al. Comparable outcomes for beta-lactam/beta-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant *Escherichia coli* or *Klebsiella pneumoniae*. *Antimicrob Resist Infect Control* **2015**; 4:14.
 59. Ng TM, Khong WX, Harris PN, et al. Empiric piperacillin-tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing *Enterobacteriaceae*. *PLoS One* **2016**; 11:e0153696.
 60. Tamma PD, Han JH, Rock C, et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia. *Clin Infect Dis* **2015**; 60:1319-25.
 61. Tsai HY, Chen YH, Tang HJ, et al. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing *Proteus mirabilis*. *Diagn Microbiol Infect Dis* **2014**; 80:222-6.
 62. Nasir N, Ahmed S, Razi S, Awan S, Mahmood SF. Risk factors for mortality of patients with ceftriaxone resistant *E. coli* bacteremia receiving carbapenem versus beta lactam/beta lactamase inhibitor therapy. *BMC Res Notes* **2019**; 12:611.
 63. Xiao T, Yang K, Zhou Y, et al. Risk factors and outcomes in non-transplant patients with extended-spectrum beta-lactamase-producing *Escherichia coli* bacteremia: a retrospective study from 2013 to 2016. *Antimicrob Resist Infect Control* **2019**; 8:144.
 64. Ko JH, Lee NR, Joo EJ, et al. Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing *Enterobacteriaceae*: a propensity score weighted multicenter cohort study. *Eur J Clin Microbiol Infect Dis* **2018**; 37:305-11.
 65. Meini S, Laureano R, Tascini C, et al. Clinical outcomes of elderly patients with bloodstream infections due to extended-spectrum beta-lactamase-producing *Enterobacteriaceae* in an Italian Internal Medicine ward. *Eur J Intern Med* **2018**; 48:50-6.
 66. Ofer-Friedman H, Shefler C, Sharma S, et al. Carbapenems versus piperacillin-tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum beta-lactamase-producing *Enterobacteriaceae*. *Infect Control Hosp Epidemiol* **2015**; 36:981-5.
 67. Tamma PD, Rodríguez-Baño J. The use of noncarbapenem beta-lactams for the treatment of extended-spectrum beta-lactamase infections. *Clin Infect Dis* **2017**; 64:972-80.
 68. Livermore DM, Andrews JM, Hawkey PM, et al. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? *J Antimicrob Chemother* **2012**; 67:1569-77.
 69. Zhou M, Wang Y, Liu C, et al. Comparison of five commonly used automated susceptibility testing methods for accuracy in the China Antimicrobial Resistance Surveillance System (CARSS) hospitals. *Infect Drug Resist* **2018**; 11:1347-58.
 70. Paterson DL, Henderson A, Harris PNA. Current evidence for therapy of ceftriaxone-resistant gram-negative bacteremia. *Curr Opin Infect Dis* **2020**; 33:78-85.

71. Livermore DM, Day M, Cleary P, et al. OXA-1 β -lactamase and non-susceptibility to penicillin/ β -lactamase inhibitor combinations among ESBL-producing *Escherichia coli*. *J Antimicrob Chemother* **2019**; 74:326–33.
72. Smith KP, Brennan-Krohn T, Weir S, Kirby JE. Improved accuracy of cefepime susceptibility testing for extended-spectrum-beta-lactamase-producing *Enterobacteriaceae* with an on-demand digital dispensing method. *J Clin Microbiol* **2017**; 55:470–8.
73. Kim SA, Altshuler J, Paris D, Fedorenko M. Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum β -lactamase-producing *Enterobacteriaceae*. *Int J Antimicrob Agents* **2018**; 51:155–8.
74. Wang R, Cosgrove SE, Tschudin-Sutter S, et al. Cefepime therapy for cefepime-susceptible extended-spectrum β -lactamase-producing *Enterobacteriaceae* bacteremia. *Open Forum Infect Dis* **2016**; 3:ofw132.
75. Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing *Enterobacteriaceae*: MIC matters. *Clin Infect Dis* **2013**; 56:488–95.
76. Chopra T, Marchaim D, Veltman J, et al. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum- β -lactamase-producing *Klebsiella pneumoniae* and *Escherichia coli*. *Antimicrob Agents Chemother* **2012**; 56:3936–42.
77. Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. *Antimicrob Agents Chemother* **2003**; 47:3442–7.
78. Lepeule R, Leflon-Guibout V, Vanjak D, et al. Clinical spectrum of urine cultures positive for ESBL-producing *Escherichia coli* in hospitalized patients and impact on antibiotic use. *Med Mal Infect* **2014**; 44:530–4.
79. Stewart AG, Cottrell K, Henderson A, et al. *In vitro* activity of Cefotetan against ESBL-producing *Escherichia coli* and *Klebsiella pneumoniae* bloodstream isolates from the MERINO Trial. *Microbiol Spectr* **2021**; 9:e0022621.
80. Lee CH, Su LH, Tang YF, Liu JW. Treatment of ESBL-producing *Klebsiella pneumoniae* bacteraemia with carbapenem or flomoxef: a retrospective study and laboratory analysis of the isolates. *J Antimicrob Chemother* **2006**; 58:1074–7.
81. Yang CC, Li SH, Chuang FR, et al. Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing *Klebsiella pneumoniae* in patients on maintenance hemodialysis. *BMC Infect Dis* **2012**; 12:206.
82. Doi A, Shimada T, Harada S, Iwata K, Kamiya T. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing *Enterobacteriaceae*. *Int J Infect Dis* **2013**; 17:e159–63.
83. Pilmis B, Parize P, Zahar JR, Lortholary O. Alternatives to carbapenems for infections caused by ESBL-producing *Enterobacteriaceae*. *Eur J Clin Microbiol Infect Dis* **2014**; 33:1263–5.
84. Matsumura Y, Yamamoto M, Nagao M, et al. Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum- β -lactamase-producing *Escherichia coli* bacteremia. *Antimicrob Agents Chemother* **2015**; 59:5107–13.
85. Lee CH, Su LH, Chen FJ, et al. Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum β -lactamase-producing *Escherichia coli* or *Klebsiella pneumoniae* with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study. *International Journal of Antimicrobial Agents* **2015**; 46:610–5.
86. Fukuchi T, Iwata K, Kobayashi S, Nakamura T, Ohji G. Cefmetazole for bacteremia caused by ESBL-producing *Enterobacteriaceae* comparing with carbapenems. *BMC Infect Dis* **2016**; 16:427.
87. Senard O, Lafaurie M, Lesprit P, et al. Efficacy of cefoxitin versus carbapenem in febrile male urinary tract infections caused by extended spectrum beta-lactamase-producing *Escherichia coli*: a multicenter retrospective cohort study with propensity score analysis. *Eur J Clin Microbiol Infect Dis* **2020**; 39:121–9.
88. Centers for Disease Control and Prevention. Facility guidance for control of carbapenem-resistant *Enterobacteriaceae* (CRE): November 2015 update - CRE toolkit, **2015**. Available at: <https://www.cdc.gov/hai/pdfs/cre-guidance-508.pdf>.
89. Shropshire WC, Aitken SL, Pifer R, et al. IS26-mediated amplification of *bla*OXA-1 and *bla*CTX-M-15 with concurrent outer membrane porin disruption associated with *de novo* carbapenem resistance in a recurrent bacteraemia cohort. *J Antimicrob Chemother* **2021**; 76:385–95.
90. Sabour S, Huang Y, Bhatnagar A, et al. Detection and characterization of targeted carbapenem-resistant healthcare-associated threats: findings from the antibiotic resistance laboratory network, 2017 to 2019. *Antimicrob Agents Chemother* **2021**; 65:e0110521.
91. van Duin D, Arias CA, Komarow L, et al. Molecular and clinical epidemiology of carbapenem-resistant *Enterobacteriales* in the USA (CRACKLE-2): a prospective cohort study. *Lancet Infect Dis* **2020**; 20:731–741.
92. Aitken SL, Tarrand JJ, Deshpande LM, et al. High rates of nonsusceptibility to ceftazidime-avibactam and identification of New Delhi metallo- β -lactamase production in *Enterobacteriaceae* bloodstream infections at a major cancer center. *Clin Infect Dis* **2016**; 63:954–8.
93. Senchyna F, Gaur RL, Sandlund J, et al. Diversity of resistance mechanisms in carbapenem-resistant *Enterobacteriaceae* at a health care system in Northern California, from 2013 to 2016. *Diagn Microbiol Infect Dis* **2019**; 93:250–7.
94. Tamma PD, Simmer PJ. Phenotypic detection of carbapenemase-producing organisms from clinical isolates. *J Clin Microbiol* **2018**; 56:e01140-18.
95. Tamma PD, Goodman KE, Harris AD, et al. Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant *Enterobacteriaceae* bacteremia. *Clin Infect Dis* **2017**; 64:257–64.
96. Bulik CC, Fauntleroy KA, Jenkins SG, et al. Comparison of meropenem MICs and susceptibilities for carbapenemase-producing *Klebsiella pneumoniae* isolates by various testing methods. *J Clin Microbiol* **2010**; 48:2402–6.
97. Sutherland CA, Verastegui JE, Nicolau DP. *In vitro* potency of amikacin and comparators against *E. coli*, *K. pneumoniae* and *P. aeruginosa* respiratory and blood isolates. *Ann Clin Microbiol Antimicrob* **2016**; 15:39.
98. Castanheira M, Davis AP, Mendes RE, Serio AW, Krause KM, Flamm RK. *In vitro* activity of plazomicin against gram-negative and gram-positive isolates collected from U.S. hospitals and comparative activities of aminoglycosides against carbapenem-resistant *Enterobacteriaceae* and isolates carrying carbapenemase genes. *Antimicrob Agents Chemother* **2018**; 62:e00313-18.
99. Castanheira M, Sader HS, Mendes RE, Jones RN. Activity of plazomicin tested against *Enterobacteriales* isolates collected from U.S. hospitals in 2016–2017: effect of different breakpoint criteria on susceptibility rates among aminoglycosides. *Antimicrob Agents Chemother* **2020**; 64:e02418-19.
100. Wagenlehner FM, Sobel JD, Newell P, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. *Clin Infect Dis* **2016**; 63:754–62.
101. Carmeli Y, Armstrong J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant *Enterobacteriaceae* and *Pseudomonas aeruginosa* complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. *Lancet Infect Dis* **2016**; 16:661–73.
102. Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. *JAMA* **2018**; 319:788–99.
103. Portsmouth S, van Veenhuizen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. *Lancet Infect Dis* **2018**; 18:1319–28.
104. Sims M, Mariyanovski V, McLeroth P, et al. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. *J Antimicrob Chemother* **2017**; 72:2616–26.
105. Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. *Lancet Infect Dis* **2021**; 21:226–40.
106. Sorli L, Luque S, Li J, et al. Colistin for the treatment of urinary tract infections caused by extremely drug-resistant *Pseudomonas aeruginosa*: dose is critical. *J Infect* **2019**; 79:253–61.
107. Sandri AM, Landersdorfer CB, Jacob J, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. *Clin Infect Dis* **2013**; 57:524–31.
108. Brown CT, Irber L. sourmash: a library for MinHash sketching of DNA. *J Open Source Softw* **2016**; 1:27.
109. de Jonge BL, Karlowsky JA, Kazmierczak KM, et al. *In vitro* susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible *Enterobacteriaceae* isolates collected during the INFORM global surveillance study (2012 to 2014). *Antimicrob Agents Chemother* **2016**; 60:3163–9.
110. Spiliopoulou I, Kazmierczak K, Stone GG. *In vitro* activity of ceftazidime/avibactam against isolates of carbapenem-non-susceptible *Enterobacteriaceae* collected during the INFORM global surveillance programme (2015-17). *J Antimicrob Chemother* **2020**; 75:384–91.

111. Castanheira M, Doyle TB, Collingsworth TD, et al. Increasing frequency of OXA-48-producing *Enterobacterales* worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates. *J Antimicrob Chemother* **2021**;76:3125–34.
112. Castanheira M, Doyle TB, Kantro V, Mendes RE, Shortridge D. Meropenem-vaborbactam activity against carbapenem-resistant *Enterobacterales* isolates collected in U.S. hospitals during 2016 to 2018. *Antimicrob Agents Chemother* **2020**; 64:e01951-19.
113. Pfaller MA, Huband MD, Mendes RE, Flamm RK, Castanheira M. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant *Enterobacteriaceae* from the 2015 meropenem/vaborbactam surveillance programme. *Int J Antimicrob Agents* **2018**; 52:144–50.
114. Johnston BD, Thuras P, Porter SB, et al. Activity of imipenem-relebactam against carbapenem-resistant *Escherichia coli* isolates from the United States in relation to clonal background, resistance genes, coresistance, and region. *Antimicrob Agents Chemother* **2020**; 64:e02408-19.
115. Horwich-Scholefield S, Lloyd T, Varghese V, Yette E, Huang S, Pandori M. Imipenem-relebactam susceptibility and genotypic characteristics of carbapenem-resistant *Enterobacterales* (CRE) identified during population-based surveillance. *Antimicrob Agents Chemother* **2021**;65: e0228820.
116. Castanheira M, Doyle TB, Hubler C, Sader HS, Mendes RE. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant *Enterobacterales*: Ompk36 L3 alterations and β -lactamases with ceftazidime hydrolytic activity lead to elevated MIC values. *Int J Antimicrob Agents* **2020**; 56:106011.
117. Haidar G, Clancy CJ, Chen L, et al. Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant *Enterobacteriaceae*. *Antimicrob Agents Chemother* **2017**; 61:e00642-17.
118. Canver MC, Satlin MJ, Westblade LF, et al. Activity of imipenem-relebactam and comparator agents against genetically characterized isolates of carbapenem-resistant *Enterobacteriaceae*. *Antimicrob Agents Chemother* **2019**; 63:e00672-19.
119. Galani I, Souli M, Nafplioti K, et al. In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing *Klebsiella pneumoniae* isolated in Greek hospitals in 2015–2016. *Eur J Clin Microbiol Infect Dis* **2019**; 38:1143–50.
120. Daikos GL, Tsaousi S, Tzouveleki LS, et al. Carbapenemase-producing *Klebsiella pneumoniae* bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. *Antimicrob Agents Chemother* **2014**; 58:2322–8.
121. Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. *J Antimicrob Chemother* **2009**; 64:142–50.
122. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. *J Clin Pharmacol* **2003**; 43:1116–23.
123. Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. *J Clin Pharmacol* **2006**; 46:1171–8.
124. Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant *Klebsiella pneumoniae* bacteremia. *Antimicrob Agents Chemother* **2017**; 61:e00883-17.
125. van Duin D, Lok JJ, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant *Enterobacteriaceae*. *Clin Infect Dis* **2018**; 66:163–71.
126. Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant *Enterobacteriaceae* infections: the TANGO II randomized clinical trial. *Infect Dis Ther* **2018**; 7:439–55.
127. Motsch J, Murta de Oliveira C, Stus V, et al. RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. *Clin Infect Dis* **2020**; 70:1799–808.
128. Karakos I, Daikos GL, Gkoufa A, et al. Ceftazidime/avibactam in the era of carbapenemase-producing *Klebsiella pneumoniae*: experience from a national registry study. *J Antimicrob Chemother* **2021**; 76:775–83.
129. Hakeam HA, Alsahl H, Alhabtain L, Alassaf S, Al Duhailib Z, Althawadi S. Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant *Enterobacteriaceae* bacteremia. *Int J Infect Dis* **2021**; 109:1–7.
130. Castón JJ, Lacort-Peralta I, Martín-Dávila P, et al. Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing *Enterobacteriaceae* in hematologic patients. *Int J Infect Dis* **2017**; 59:118–23.
131. Alraddadi BM, Saeedi M, Qutub M, Alshukairi A, Hassanien A, Wali G. Efficacy of ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant *Enterobacteriaceae*. *BMC Infect Dis* **2019**; 19:772.
132. Tumbarello M, Treccarichi EM, Corona A, et al. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae*. *Clin Infect Dis* **2019**; 68:355–64.
133. Kazmierczak KM, Tsuji M, Wise MG, et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo- β -lactamase-producing isolates (SIDERO-WT-2014 Study). *Int J Antimicrob Agents* **2019**; 53:177–84.
134. Boyd SE, Livermore DM, Hooper DC, Hope WW. Metallo- β -lactamases: structure, function, epidemiology, treatment options, and the development pipeline. *Antimicrob Agents Chemother* **2020**; 64:e00397-20.
135. Tamma PD, Hsu AJ. Defining the role of novel β -lactam agents that target carbapenem-resistant gram-negative organisms. *J Pediatric Infect Dis Soc* **2019**; 8:251–60.
136. Alosaimy S, Jorgensen SCJ, Lagaf AM, et al. Real-world multicenter analysis of clinical outcomes and safety of meropenem-vaborbactam in patients treated for serious gram-negative bacterial infections. *Open Forum Infect Dis* **2020**; 7: ofaa051.
137. Ackley R, Roshdy D, Meredith J, et al. Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant *Enterobacteriaceae* infections. *Antimicrob Agents Chemother* **2020**; 64: e02313-19.
138. Kulengowski B, Burgess DS. Imipenem/relebactam activity compared to other antimicrobials against non-MBL-producing carbapenem-resistant *Enterobacteriaceae* from an academic medical center. *Pathog Dis* **2019**; 77:ftz040.
139. Walkty A, Karlowsky JA, Baxter MR, et al. In vitro activity of imipenem-relebactam against various resistance phenotypes/genotypes of *Enterobacterales* and *Pseudomonas aeruginosa* isolated from patients across Canada as part of the CANWARD study, 2016–2019. *Diagn Microbiol Infect Dis* **2021**; 101:115418.
140. Yang TY, Hsieh YJ, Kao LT, et al. Activities of imipenem-relebactam combination against carbapenem-nonsusceptible *Enterobacteriaceae* in Taiwan. *J Microbiol Immunol Infect* **2022**;55:86–94.
141. Lob SH, Karlowsky JA, Young K, et al. In vitro activity of imipenem-relebactam against resistant phenotypes of *Enterobacteriaceae* and *Pseudomonas aeruginosa* isolated from intraabdominal and urinary tract infection samples – SMART Surveillance Europe 2015–2017. *J Med Microbiol* **2020**; 69:207–17.
142. Papp-Wallace KM, Barnes MD, Alsop J, et al. Relebactam is a potent inhibitor of the KPC-2 β -lactamase and restores imipenem susceptibility in KPC-producing *Enterobacteriaceae*. *Antimicrob Agents Chemother* **2018**; 62:e00174-18.
143. McCreary EK, Heil EL, Tamma PD. New perspectives on antimicrobial agents: cefiderocol. *Antimicrob Agents Chemother* **2021**; 65:e0217120.
144. Shaw E, Rombauts A, Tubau F, et al. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing *Klebsiella pneumoniae* infection. *J Antimicrob Chemother* **2018**; 73:1104–6.
145. Hobson CA, Bonacorsi S, Fahd M, et al. Successful treatment of bacteremia due to NDM-1-producing *Morganella morganii* with aztreonam and ceftazidime-avibactam combination in a pediatric patient with hematologic malignancy. *Antimicrob Agents Chemother* **2019**; 63:e02463-18.
146. Biagi M, Wu T, Lee M, Patel S, Butler D, Wenzler E. Searching for the optimal treatment for metallo- and serine- β -lactamase producing *Enterobacteriaceae*: aztreonam in combination with ceftazidime-avibactam or meropenem-vaborbactam. *Antimicrob Agents Chemother* **2019**;63:e01426-19.
147. Sieswerda E, van den Brand M, van den Berg RB, et al. Successful rescue treatment of sepsis due to a pandrug-resistant, NDM-producing *Klebsiella pneumoniae* using aztreonam powder for nebulizer solution as intravenous therapy in combination with ceftazidime/avibactam. *J Antimicrob Chemother* **2020**; 75: 773–5.
148. Benchetrit L, Mathy V, Armand-Lefevre L, Bouadma L, Timsit JF. Successful treatment of septic shock due to NDM-1-producing *Klebsiella pneumoniae* using ceftazidime/avibactam combined with aztreonam in solid organ transplant recipients: report of two cases. *Int J Antimicrob Agents* **2020**; 55:105842.
149. Falcone M, Daikos GL, Tiseo G, et al. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo- β -lactamase-producing *Enterobacterales*. *Clin Infect Dis* **2021**; 72:1871–8.
150. Lodise TP, Smith NM, O'Donnell N, et al. Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against

- NDM-1-producing *Enterobacteriaceae* using a hollow-fibre infection model. *J Antimicrob Chemother* **2020**; 75:2622–32.
151. Dobias J, Denervaud-Tendon V, Poirel L, Nordmann P. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant gram-negative pathogens. *Eur J Clin Microbiol Infect Dis* **2017**; 36:2319–27.
 152. De la Calle C, Rodriguez O, Morata L, et al. Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing *Enterobacteriaceae* in patients treated with ceftazidime-avibactam. *Int J Antimicrob Agents* **2019**; 53:520–4.
 153. Humphries RM, Yang S, Hemarajata P, et al. First report of ceftazidime-avibactam resistance in a KPC-3-expressing *Klebsiella pneumoniae* isolate. *Antimicrob Agents Chemother* **2015**; 59:6605–7.
 154. Winkler ML, Papp-Wallace KM, Bonomo RA. Activity of ceftazidime/avibactam against isogenic strains of *Escherichia coli* containing KPC and SHV beta-lactamases with single amino acid substitutions in the Omega-loop. *J Antimicrob Chemother* **2015**; 70:2279–86.
 155. Livermore DM, Warner M, Jamrozny D, et al. *In vitro* selection of ceftazidime-avibactam resistance in *Enterobacteriaceae* with KPC-3 carbapenemase. *Antimicrob Agents Chemother* **2015**; 59:5324–30.
 156. Shields RK, Chen L, Cheng S, et al. Emergence of ceftazidime-avibactam resistance due to plasmid-borne *bla*_{KPC-3} mutations during treatment of carbapenem-resistant *Klebsiella pneumoniae* infections. *Antimicrob Agents Chemother* **2017**; 61:e02097-16.
 157. Shields RK, Potoski BA, Haidar G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant *Enterobacteriaceae* infections. *Clin Infect Dis* **2016**; 63:1615–8.
 158. Compain F, Arthur M. Impaired inhibition by avibactam and resistance to the ceftazidime-avibactam combination due to the D¹⁷⁹Y substitution in the KPC-2 beta-lactamase. *Antimicrob Agents Chemother* **2017**; 61:e00451-17.
 159. Giddins MJ, Macesic N, Annavajhala MK, et al. Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in *bla*_{KPC-2}-harboring *Klebsiella pneumoniae* sequence type 307 isolates. *Antimicrob Agents Chemother* **2018**; 62:e02101-17.
 160. Göttig S, Frank D, Mungo E, et al. Emergence of ceftazidime/avibactam resistance in KPC-3-producing *Klebsiella pneumoniae* in vivo. *J Antimicrob Chemother* **2019**; 74:3211–6.
 161. Castanheira M, Arends SJR, Davis AP, Woosley LN, Bhalodi AA, MacVane SH. Analyses of a ceftazidime-avibactam-resistant *Citrobacter freundii* isolate carrying *bla*_{KPC-2} reveals a heterogeneous population and reversible genotype. *mSphere* **2018**; 3:e00408-18.
 162. Wilson WR, Kline EG, Jones CE, et al. Effects of KPC variant and porin genotype on the *in vitro* activity of meropenem-vaborbactam against carbapenem-resistant *Enterobacteriaceae*. *Antimicrob Agents Chemother* **2019**; 63:e02048-18.
 163. Zhang P, Shi Q, Hu H, et al. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant *Klebsiella pneumoniae* in China. *Clin Microbiol Infect* **2020**; 26:124.e1–4.
 164. Venditti C, Nisii C, D'Arezzo S, et al. Molecular and phenotypical characterization of two cases of antibiotic-driven ceftazidime-avibactam resistance in *bla*_{KPC-3}-harboring *Klebsiella pneumoniae*. *Infect Drug Resist* **2019**; 12:1935–40.
 165. Cano A, Guzmán-Puche J, García-Gutiérrez M, et al. Use of carbapenems in the combined treatment of emerging ceftazidime/avibactam-resistant and carbapenem-susceptible KPC-producing *Klebsiella pneumoniae* infections: report of a case and review of the literature. *J Glob Antimicrob Resist* **2020**; 22:9–12.
 166. Gaibani P, Re MC, Campoli C, Viale PL, Ambretti S. Bloodstream infection caused by KPC-producing *Klebsiella pneumoniae* resistant to ceftazidime/avibactam: epidemiology and genomic characterization. *Clin Microbiol Infect* **2020**; 26:516.e1–4.
 167. Hemarajata P, Humphries RM. Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2. *J Antimicrob Chemother* **2019**; 74:1241–3.
 168. Räisänen K, Koivula I, Ilmavirta H, et al. Emergence of ceftazidime-avibactam-resistant *Klebsiella pneumoniae* during treatment, Finland, December 2018. *Euro Surveill* **2019**; 24:1900256.
 169. Zhang Y, Kashikar A, Brown CA, Denys G, Bush K. Unusual *Escherichia coli* PBP₃ insertion sequence identified from a collection of carbapenem-resistant *Enterobacteriaceae* tested *in vitro* with a combination of ceftazidime-, ceftaroline-, or aztreonam-avibactam. *Antimicrob Agents Chemother* **2017**; 61:e00389-17.
 170. Lomovskaya O, Sun D, Rubio-Aparicio D, et al. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in *Enterobacteriaceae*. *Antimicrob Agents Chemother* **2017**; 61:e01443-17.
 171. Sun D, Rubio-Aparicio D, Nelson K, Dudley MN, Lomovskaya O. Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* **2017**; 61:e01694-17.
 172. Lapuebla A, Abdallah M, Olafisoye O, et al. Activity of meropenem combined with RPX7009, a novel beta-lactamase inhibitor, against gram-negative clinical isolates in New York city. *Antimicrob Agents Chemother* **2015**; 59:4856–60.
 173. Zhou M, Yang Q, Lomovskaya O, et al. *In vitro* activity of meropenem combined with vaborbactam against KPC-producing *Enterobacteriaceae* in China. *J Antimicrob Chemother* **2018**; 73:2789–96.
 174. Castanheira M, Rhomberg PR, Flamm RK, Jones RN. Effect of the beta-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing *Enterobacteriaceae*. *Antimicrob Agents Chemother* **2016**; 60:5454–8.
 175. Griffith DC, Sabet M, Tarazi Z, Lomovskaya O, Dudley MN. Pharmacokinetics/pharmacodynamics of vaborbactam, a novel beta-lactamase inhibitor, in combination with meropenem. *Antimicrob Agents Chemother* **2019**; 63:e01659-18.
 176. Shields RK, McCreary EK, Marini RV, et al. Early experience with meropenem-vaborbactam for treatment of carbapenem-resistant *Enterobacteriaceae* infections. *Clin Infect Dis* **2020**; 71:667–671.
 177. Lapuebla A, Abdallah M, Olafisoye O, et al. Activity of imipenem with relebactam against gram-negative pathogens from New York city. *Antimicrob Agents Chemother* **2015**; 59:5029–31.
 178. Balabanian G, Rose M, Manning N, Landman D, Quale J. Effect of porins and *bla*_{KPC} expression on activity of imipenem with relebactam in *Klebsiella pneumoniae*: can antibiotic combinations overcome resistance? *Microb Drug Resist* **2018**; 24:877–81.
 179. Ito A, Nishikawa T, Ishii R, et al. 696. Mechanism of cefiderocol high MIC mutants obtained in non-clinical FoR studies. *Open Forum Infect Dis* **2018**; 5:S251.
 180. Kohira N, Nakamura R, Ito A, Nishikawa T, Ota M, Sato T. Resistance acquisition studies of cefiderocol by serial passage and *in vitro* pharmacodynamic model under human simulated exposure. 2018: Poster presented at: American Society of Microbiology Annual Meeting, Atlanta, GA, 6–11 June 2018. Poster Saturday-619.
 181. Kohira N, Ito A, Ota M, et al. Frequency of resistance acquisition and resistance mechanisms to cefiderocol. 2018: Poster presented at: American Society of Microbiology Annual Meeting, Atlanta, GA, June 6–11, 2018. Poster 619.
 182. Simner PJ, Beisken S, Bergman Y, et al. Defining baseline mechanisms of cefiderocol resistance in the *Enterobacteriales*. *Microb Drug Resist* **2022**; 28:161–70.
 183. Shields RK, Iovleva A, Kline EG, et al. Clinical evolution of AmpC-mediated ceftazidime-avibactam and cefiderocol resistance in *Enterobacter cloacae* complex following exposure to cefepime. *Clin Infect Dis* **2020**; 71:2713–6.
 184. Kawai A, McElheny CL, Iovleva A, et al. Structural basis of reduced susceptibility to ceftazidime-avibactam and cefiderocol in *Enterobacter cloacae* due to AmpC R2 loop deletion. *Antimicrob Agents Chemother* **2020**; 64:e00198–20.
 185. Simner PJ, Mostafa HH, Bergman Y, et al. Progressive development of cefiderocol resistance in *Escherichia coli* during therapy is associated with increased *bla*_{NDM-5} copy number and gene expression. *Clin Infect Dis* **2022**; 75:47–54.
 186. Papp-Wallace KM, Mack AR, Taracila MA, Bonomo RA. Resistance to novel beta-lactam-beta-lactamase inhibitor combinations: the 'price of progress'. *Infect Dis Clin North Am* **2020**; 34:773–819.
 187. Bush K, Bradford PA. Interplay between beta-lactamases and new beta-lactamase inhibitors. *Nat Rev Microbiol* **2019**; 17:295–306.
 188. Shields RK, Nguyen MH, Chen L, Press EG, Kreiswirth BN, Clancy CJ. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant *Enterobacteriaceae* infections. *Antimicrob Agents Chemother* **2018**; 62:e02497-17.
 189. Alosaimy S, Lagnf AM, Morrisette T, et al. Real-world, multicenter experience with meropenem-vaborbactam for gram-negative bacterial infections including carbapenem-resistant *Enterobacteriales* and *Pseudomonas aeruginosa*. *Open Forum Infect Dis* **2021**; 8:ofab371.
 190. Johnston BD, Thuras P, Porter SB, et al. Activity of cefiderocol, ceftazidime-avibactam, and eravacycline against carbapenem-resistant *Escherichia coli* isolates from the United States and international sites in relation to clonal background, resistance genes, coresistance, and region. *Antimicrob Agents Chemother* **2020**; 64:e00797-20.
 191. Falagas ME, Karageorgopoulos DE, Dimopoulos G. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. *Curr Drug Metab* **2009**; 10:13–21.
 192. Solomkin J, Evans D, Slepavicius A, et al. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial. *JAMA Surg* **2017**; 152:224–32.

193. Eckmann C, Montravers P, Bassetti M, et al. Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies. *J Antimicrob Chemother* **2013**; 68:ii25–35.
194. Babinchak T, Ellis-Grosse E, Dartois N, et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. *Clin Infect Dis* **2005**; 41:S354–67.
195. Zhao C, Wang X, Zhang Y, et al. In vitro activities of Eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China. *BMC Infect Dis* **2019**; 19:508.
196. Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. *J Antimicrob Chemother* **2011**; 66:1963–71.
197. Zha L, Pan L, Guo J, French N, Villanueva EV, Tefsen B. Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis. *Adv Ther* **2020**; 37:1049–64.
198. Chen Z, Shi X. Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens. *Medicine (Baltimore)* **2018**; 97:e12467.
199. De Pascale G, Montini L, Pennisi M, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. *Crit Care* **2014**; 18:R90.
200. Ni W, Han Y, Liu J, et al. Tigecycline treatment for carbapenem-resistant *Enterobacteriaceae* infections: a systematic review and meta-analysis. *Medicine (Baltimore)* **2016**; 95:e3126.
201. Morrissey I, Olesky M, Hawser S, et al. In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017. *Antimicrob Agents Chemother* **2020**; 64:e01699-19.
202. Solomkin JS, Gardovskis J, Lawrence K, et al. IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections. *Clin Infect Dis* **2019**; 69: 921–9.
203. Alosaimy S, Molina KC, Claeys KC, et al. Early experience with eravacycline for complicated infections. *Open Forum Infect Dis* **2020**; 7:ofaa071.
204. Khatri A, Lobo S, Nog R, Lee L, Wang G, Dhand A. Minocycline in the treatment of carbapenem-resistant *Klebsiella pneumoniae*. *Open Forum Infect Dis* **2017**; 4:S143.
205. Pogue JM, Neelakanta A, Mynatt RP, Sharma S, Lephart P, Kaye KS. Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center. *Clin Infect Dis* **2014**; 59:S388–93.
206. Pfaller MA, Huband MD, Shortridge D, Flamm RK. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe as part of the 2016 SENTRY antimicrobial surveillance program. *Antimicrob Agents Chemother* **2018**; 62:e02327-17.
207. Pfaller MA, Huband MD, Shortridge D, Flamm RK. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: report from the SENTRY antimicrobial surveillance program, 2016 to 2018. *Antimicrob Agents Chemother* **2020**; 64: e02488-19.
208. Dong D, Zheng Y, Chen Q, et al. In vitro activity of omadacycline against pathogens isolated from Mainland China during 2017–2018. *Eur J Clin Microbiol Infect Dis* **2020**; 39:1559–72.
209. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. *Clin Microbiol Rev* **2012**; 25:450–70.
210. Tumbarello M, Raffaelli F, Giannella M, et al. Ceftazidime-avibactam use for KPC-Kp infections: a retrospective observational multicenter study. *Clin Infect Dis* **2021**; 73:1664–76.
211. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect* **2012**; 18:268–81.
212. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant *Pseudomonas aeruginosa*: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. *Clin Microbiol Rev* **2009**; 22:582–610.
213. Wolter DJ, Lister PD. Mechanisms of beta-lactam resistance among *Pseudomonas aeruginosa*. *Curr Pharm Des* **2013**; 19:209–22.
214. Karlowsky JA, Kazmierczak KM, de Jonge BLM, Hackel MA, Sahn DF, Bradford PA. In vitro activity of aztreonam-avibactam against *Enterobacteriaceae* and *Pseudomonas aeruginosa* isolated by clinical laboratories in 40 countries from 2012 to 2015. *Antimicrob Agents Chemother* **2017**; 61: e00472-17.
215. Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahn DF. In vitro activity of ceftazidime-avibactam against clinical isolates of *Enterobacteriaceae* and *Pseudomonas aeruginosa* collected in Asia-Pacific countries: results from the INFORM global surveillance program, 2012 to 2015. *Antimicrob Agents Chemother* **2018**; 62:e02569-17.
216. Escandon-Vargas K, Reyes S, Gutierrez S, Villegas MV. The epidemiology of carbapenemases in Latin America and the Caribbean. *Expert Rev Anti Infect Ther* **2017**; 15:277–97.
217. Gajdacs M. Carbapenem-resistant but cephalosporin-susceptible *Pseudomonas aeruginosa* in urinary tract infections: opportunity for colistin sparing. *Antibiotics (Basel)* **2020**; 9:153.
218. Gill CM, Aktathorn E, Alfouzan W, et al. Elevated MICs of susceptible anti-pseudomonal cephalosporins in non-carbapenemase-producing, carbapenem-resistant *Pseudomonas aeruginosa*: implications for dose optimization. *Antimicrob Agents Chemother* **2021**;65:e0120421.
219. Khalili Y, Yekani M, Goli HR, Memar MY. Characterization of carbapenem-resistant but cephalosporin-susceptible *Pseudomonas aeruginosa*. *Acta Microbiol Immunol Hung* **2019**; 66:529–40.
220. Campana EH, Xavier DE, Petrolini FV, Cordeiro-Moura JR, Araujo MR, Gales AC. Carbapenem-resistant and cephalosporin-susceptible: a worrisome phenotype among *Pseudomonas aeruginosa* clinical isolates in Brazil. *Braz J Infect Dis* **2017**; 21:57–62.
221. Zeng ZR, Wang WP, Huang M, Shi LN, Wang Y, Shao HF. Mechanisms of carbapenem resistance in cephalosporin-susceptible *Pseudomonas aeruginosa* in China. *Diagn Microbiol Infect Dis* **2014**; 78:268–70.
222. Zaidenstein R, Miller A, Tal-Jasper R, et al. Therapeutic management of *Pseudomonas aeruginosa* bloodstream infection non-susceptible to carbapenems but susceptible to 'old' cephalosporins and/or to penicillins. *Microorganisms* **2018**; 6:9.
223. Li S, Jia X, Li C, et al. Carbapenem-resistant and cephalosporin-susceptible *Pseudomonas aeruginosa*: a notable phenotype in patients with bacteremia. *Infect Drug Resist* **2018**; 11:1225–35.
224. Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). *Lancet* **2015**; 385:1949–56.
225. Walky A, Adam H, Baxter M, et al. In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in Canadian hospitals as part of the CANWARD study, 2011–2012. *Antimicrob Agents Chemother* **2014**; 58:2554–63.
226. Athans V, Neuner EA, Hassouna H, et al. Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-resistant *Klebsiella pneumoniae* bacteremia and abscess in a liver transplant recipient. *Antimicrob Agents Chemother* **2019**; 63:e01551-18.
227. Castanheira M, Duncan LR, Mendes RE, Sader HS, Shortridge D. Activity of ceftolozane-tazobactam against *Pseudomonas aeruginosa* and *Enterobacteriaceae* isolates collected from respiratory tract specimens of hospitalized patients in the United States during 2013 to 2015. *Antimicrob Agents Chemother* **2018**; 62:e02125-17.
228. Sader HS, Castanheira M, Shortridge D, Mendes RE, Flamm RK. Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant *Enterobacteriaceae* and *Pseudomonas aeruginosa* isolates from U.S. Medical Centers, 2013 to 2016. *Antimicrob Agents Chemother* **2017**; 61:e01045-17.
229. Carvalhaes CG, Castanheira M, Sader HS, et al. Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015–2017) isolates from hospitalized patients with pneumonia in US medical centers. *Diagn Microbiol Infect Dis* **2019**; 94:93–102.
230. Shortridge D, Pfaller MA, Castanheira M, Flamm RK. Antimicrobial activity of ceftolozane-tazobactam tested against *Enterobacteriaceae* and *Pseudomonas aeruginosa* collected from patients with bloodstream infections isolated in United States hospitals (2013–2015) as part of the program to assess ceftolozane-tazobactam susceptibility (PACTS) surveillance program. *Diagn Microbiol Infect Dis* **2018**; 92:158–63.
231. Fraile-Ribot PA, Zamorano L, Orellana R, et al. Activity of imipenem-relebactam against a large collection of *Pseudomonas aeruginosa* clinical isolates and isogenic beta-lactam-resistant mutants. *Antimicrob Agents Chemother* **2020**; 64:e02165-19.
232. Sader HS, Flamm RK, Carvalhaes CG, Castanheira M. Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017–2018). *Diagn Microbiol Infect Dis* **2020**; 96:114833.
233. Sader HS, Flamm RK, Carvalhaes CG, Castanheira M. Antimicrobial susceptibility of *Pseudomonas aeruginosa* to ceftazidime-avibactam, ceftolozane-tazobactam, piperacillin-tazobactam, and meropenem stratified by U.S. census divisions: results from the 2017 INFORM program. *Antimicrob Agents Chemother* **2018**; 62:e01587-18.

234. Sader HS, Flamm RK, Dale GE, Rhomberg PR, Castanheira M. Murepavadin activity tested against contemporary (2016–17) clinical isolates of XDR *Pseudomonas aeruginosa*. *J Antimicrob Chemother* **2018**; 73:2400–4.
235. Shortridge D, Pfaller MA, Castanheira M, Flamm RK. Antimicrobial activity of ceftolozane-tazobactam tested against *Enterobacteriaceae* and *Pseudomonas aeruginosa* with various resistance patterns isolated in U.S. hospitals (2013–2016) as part of the surveillance program: program to assess ceftolozane-tazobactam susceptibility. *Microb Drug Resist* **2018**; 24:563–77.
236. Pfaller MA, Shortridge D, Sader HS, Castanheira M, Flamm RK. Ceftolozane/tazobactam activity against drug-resistant *Enterobacteriaceae* and *Pseudomonas aeruginosa* causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an antimicrobial surveillance programme (2013–2015). *Int J Antimicrob Agents* **2018**; 51:181–9.
237. Pfaller MA, Shortridge D, Sader HS, Gales A, Castanheira M, Flamm RK. Ceftolozane-tazobactam activity against drug-resistant *Enterobacteriaceae* and *Pseudomonas aeruginosa* causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013–2015). *Braz J Infect Dis* **2017**; 21:627–37.
238. Pfaller MA, Shortridge D, Sader HS, Flamm RK, Castanheira M. Ceftolozane-tazobactam activity against drug-resistant *Enterobacteriaceae* and *Pseudomonas aeruginosa* causing healthcare-associated infections in Australia and New Zealand: report from an antimicrobial surveillance program (2013–2015). *J Glob Antimicrob Resist* **2017**; 10:186–94.
239. Shortridge D, Castanheira M, Pfaller MA, Flamm RK. Ceftolozane-tazobactam activity against *Pseudomonas aeruginosa* clinical isolates from U.S. hospitals: report from the PACTS antimicrobial surveillance program, 2012 to 2015. *Antimicrob Agents Chemother* **2017**; 61: e00465-17.
240. Pfaller MA, Bassetti M, Duncan LR, Castanheira M. Ceftolozane/tazobactam activity against drug-resistant *Enterobacteriaceae* and *Pseudomonas aeruginosa* causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–15). *J Antimicrob Chemother* **2017**; 72:1386–95.
241. Sader HS, Castanheira M, Mendes RE, et al. Frequency and antimicrobial susceptibility of gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015–17). *J Antimicrob Chemother* **2018**; 73:3053–9.
242. Sader HS, Carvalhaes CG, Streit JM, Doyle TB, Castanheira M. Antimicrobial activity of ceftazidime-avibactam, ceftolozane-tazobactam and comparators tested against *Pseudomonas aeruginosa* and *Klebsiella pneumoniae* isolates from United States Medical Centers in 2016–2018. *Microb Drug Resist* **2021**; 27:342–9.
243. Sader HS, Castanheira M, Flamm RK, Farrell DJ, Jones RN. Antimicrobial activity of ceftazidime-avibactam against gram-negative organisms collected from U.S. medical centers in 2012. *Antimicrob Agents Chemother* **2014**; 58:1684–92.
244. Sader HS, Castanheira M, Mendes RE, Flamm RK, Farrell DJ, Jones RN. Ceftazidime-avibactam activity against multidrug-resistant *Pseudomonas aeruginosa* isolated in U.S. medical centers in 2012 and 2013. *Antimicrob Agents Chemother* **2015**; 59:3656–9.
245. Sader HS, Huband MD, Castanheira M, Flamm RK. *Pseudomonas aeruginosa* antimicrobial susceptibility results from four years (2012 to 2015) of the international network for optimal resistance monitoring program in the United States. *Antimicrob Agents Chemother* **2017**; 61:e02252-16.
246. Sader HS, Castanheira M, Flamm RK. Antimicrobial activity of ceftazidime-avibactam against gram-negative bacteria isolated from patients hospitalized with pneumonia in U.S. Medical Centers, 2011 to 2015. *Antimicrob Agents Chemother* **2017**; 61:e02083-16.
247. Sader HS, Castanheira M, Jones RN, Flamm RK. Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013–2014). *Diagn Microbiol Infect Dis* **2017**; 87:261–5.
248. Sader HS, Castanheira M, Flamm RK, Jones RN. Antimicrobial activities of ceftazidime-avibactam and comparator agents against gram-negative organisms isolated from patients with urinary tract infections in U.S. Medical Centers, 2012 to 2014. *Antimicrob Agents Chemother* **2016**; 60:4355–60.
249. Sader HS, Castanheira M, Flamm RK, Huband MD, Jones RN. Ceftazidime-avibactam activity against aerobic gram negative organisms isolated from intra-abdominal infections in United States hospitals, 2012–2014. *Surg Infect (Larchmt)* **2016**; 17:473–8.
250. Huband MD, Castanheira M, Flamm RK, Farrell DJ, Jones RN, Sader HS. In vitro activity of ceftazidime-avibactam against contemporary *Pseudomonas aeruginosa* isolates from U.S. Medical centers by census region, 2014. *Antimicrob Agents Chemother* **2016**; 60:2537–41.
251. Sader HS, Castanheira M, Farrell DJ, Flamm RK, Jones RN. Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible *Citrobacter* spp., *Enterobacter* spp., *Serratia marcescens*, and *Pseudomonas aeruginosa* from United States medical centers (2011–2014). *Diagn Microbiol Infect Dis* **2015**; 83:389–94.
252. Sader HS, Castanheira M, Flamm RK, Mendes RE, Farrell DJ, Jones RN. Ceftazidime/avibactam tested against gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. *Int J Antimicrob Agents* **2015**; 46:53–9.
253. Lob SH, DePestel DD, DeRyke CA, et al. Ceftolozane/tazobactam and imipenem/relebactam cross-susceptibility among clinical isolates of *Pseudomonas aeruginosa* from patients with respiratory tract infections in ICU and non-ICU wards-SMART United States 2017–2019. *Open Forum Infect Dis* **2021**; 8:ofab320.
254. Lob SH, Hackel MA, Young K, Motyl MR, Sahn DF. Activity of imipenem/relebactam and comparators against gram-negative pathogens from patients with bloodstream infections in the United States and Canada - SMART 2018–2019. *Diagn Microbiol Infect Dis* **2021**; 100:115421.
255. Kuo SC, Wang YC, Tan MC, et al. In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-nonsusceptible gram-negative bacilli from Taiwan. *J Antimicrob Chemother* **2021**; 76:2071–8.
256. Karlowsky JA, Lob SH, Young K, Motyl MR, Sahn DF. In vitro activity of imipenem/relebactam against gram-negative bacilli from pediatric patients-study for monitoring antimicrobial resistance trends (SMART) global surveillance program 2015–2017. *J Pediatric Infect Dis Soc* **2021**; 10:274–81.
257. Karlowsky JA, Lob SH, Raddatz J, et al. In vitro activity of imipenem/relebactam and ceftolozane/tazobactam against clinical isolates of gram-negative bacilli with difficult-to-treat resistance and multidrug-resistant phenotypes - SMART United States 2015–2017. *Clin Infect Dis* **2020**; 72:2112–20.
258. Lob SH, Hackel MA, Kazmierczak KM, et al. In vitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015: results from the SMART global surveillance program. *Diagn Microbiol Infect Dis* **2017**; 88:171–6.
259. Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahn DF. In-vitro activity of imipenem/relebactam and key beta-lactam agents against gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015–2017. *Int J Antimicrob Agents* **2020**; 55:105841.
260. Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahn DF. In vitro activity of imipenem/relebactam against *Enterobacteriaceae* and *Pseudomonas aeruginosa* isolated from intraabdominal and urinary tract infection samples: SMART Surveillance United States 2015–2017. *J Glob Antimicrob Resist* **2020**; 21:223–8.
261. Karlowsky JA, Lob SH, Young K, Motyl MR, Sahn DF. Activity of imipenem-relebactam against multidrug-resistant *Pseudomonas aeruginosa* from the United States - SMART 2015–2017. *Diagn Microbiol Infect Dis* **2019**; 95:212–5.
262. Lob SH, Karlowsky JA, Young K, et al. Activity of imipenem/relebactam against MDR *Pseudomonas aeruginosa* in Europe: SMART 2015–17. *J Antimicrob Chemother* **2019**; 74:2284–8.
263. Karlowsky JA, Lob SH, Young K, Motyl MR, Sahn DF. Activity of imipenem/relebactam against *Pseudomonas aeruginosa* with antimicrobial-resistant phenotypes from seven global regions: SMART 2015–2016. *J Glob Antimicrob Resist* **2018**; 15:140–7.
264. Lob SH, Hoban DJ, Young K, Motyl MR, Sahn DF. Activity of imipenem/relebactam against gram-negative bacilli from global ICU and non-ICU wards: SMART 2015–2016. *J Glob Antimicrob Resist* **2018**; 15:12–9.
265. Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahn DF. In vitro activity of imipenem-relebactam against clinical isolates of gram-negative bacilli isolated in hospital laboratories in the United States as part of the SMART 2016 program. *Antimicrob Agents Chemother* **2018**; 62: e00169-18.
266. Karlowsky JA, Lob SH, Kazmierczak KM, et al. In vitro activity of imipenem/relebactam against gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme. *J Antimicrob Chemother* **2018**; 73:1872–9.
267. Lob SH, Hackel MA, Kazmierczak KM, et al. In vitro activity of imipenem-relebactam against gram-negative ESKAPE pathogens isolated by clinical laboratories in the United States in 2015 (results from the SMART global surveillance program). *Antimicrob Agents Chemother* **2017**; 61:e02209-16.
268. Zhang H, Jia P, Zhu Y, et al. Susceptibility to imipenem/relebactam of *Pseudomonas aeruginosa* and acinetobacter baumannii isolates from Chinese intra-abdominal, respiratory and urinary tract infections: SMART 2015 to 2018. *Infect Drug Resist* **2021**; 14:3509–18.
269. Pogue JM, Kaye KS, Veve MP, et al. Ceftolozane/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant *Pseudomonas aeruginosa*. *Clin Infect Dis* **2020**; 71:304–10.
270. Kollef MH, Novacek M, Kivistik U, et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised,

- controlled, double-blind, phase 3, non-inferiority trial. *Lancet Infect Dis* **2019**; 19:1299–311.
271. Torres A, Zhong N, Pacht J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. *Lancet Infect Dis* **2018**; 18:285–95.
 272. Mazuski JE, Gasink LB, Armstrong J, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. *Clin Infect Dis* **2016**; 62:1380–9.
 273. Lucasti C, Hershberger E, Miller B, et al. Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. *Antimicrob Agents Chemother* **2014**; 58:5350–7.
 274. Lucasti C, Vasile L, Sandesc D, et al. Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection. *Antimicrob Agents Chemother* **2016**; 60:6234–43.
 275. Titov I, Wunderink RG, Roquilly A, et al. A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem/cilastatin/relebactam versus piperacillin/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI₂ study). *Clin Infect Dis* **2021**; 73:e4539–e4548.
 276. Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIA). *Clin Infect Dis* **2015**; 60:1462–71.
 277. Sader HS, Duncan LR, Doyle TB, Castanheira M. Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against *Pseudomonas aeruginosa* from cystic fibrosis patients. *JAC Antimicrob Resist* **2021**; 3:dlab126.
 278. Atkin SD, Abid S, Foster M, et al. Multidrug-resistant *Pseudomonas aeruginosa* from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime-avibactam. *Infect Drug Resist* **2018**; 11:1499–510.
 279. Stone GG, Newell P, Gasink LB, et al. Clinical activity of ceftazidime/avibactam against MDR *Enterobacteriaceae* and *Pseudomonas aeruginosa*: pooled data from the ceftazidime/avibactam Phase III clinical trial programme. *J Antimicrob Chemother* **2018**; 73:2519–23.
 280. Ito A, Sato T, Ota M, et al. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria. *Antimicrob Agents Chemother* **2018**; 62:e01454–17.
 281. Rolston KVI, Gerges B, Shelburne S, Aitken SL, Raad I, Prince RA. Activity of cefiderocol and comparators against isolates from cancer patients. *Antimicrob Agents Chemother* **2020**; 64: e01955–19.
 282. Falagas ME, Skalikis T, Vardakas KZ, Legakis NJ, Hellenic Cefiderocol Study G. Activity of cefiderocol (S-649266) against carbapenem-resistant gram-negative bacteria collected from inpatients in Greek hospitals. *J Antimicrob Chemother* **2017**; 72:1704–8.
 283. Golden AR, Adam HJ, Baxter M, et al. In vitro activity of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacilli isolated from patients in Canadian intensive care units. *Diagn Microbiol Infect Dis* **2020**; 97:115012.
 284. Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahn DF. In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of gram-negative bacilli collected worldwide in 2014 to 2016. *Antimicrob Agents Chemother* **2018**; 62: e01968–17.
 285. Karlowsky JA, Hackel MA, Tsuji M, Yamano Y, Echols R, Sahn DF. In vitro activity of cefiderocol, a siderophore cephalosporin, against gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015–2016: SIDERO-WT-2015. *Int J Antimicrob Agents* **2019**; 53:456–66.
 286. Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahn DF. In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 study). *Antimicrob Agents Chemother* **2017**; 61:e00093–17.
 287. Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. *Lancet Infect Dis* **2021**; 21:226–40.
 288. Skoglund E, Abodakpi H, Rios R, et al. In vivo resistance to ceftolozane/tazobactam in *Pseudomonas aeruginosa* arising by AmpC- and non-AmpC-mediated pathways. *Case Rep Infect Dis* **2018**; 2018:9095203.
 289. Berrazeg M, Jeannot K, Ntsogo Enguene VY, et al. Mutations in beta-lactamase AmpC increase resistance of *Pseudomonas aeruginosa* isolates to antipseudomonal cephalosporins. *Antimicrob Agents Chemother* **2015**; 59:6248–55.
 290. Fraile-Ribot PA, Cabot G, Mulet X, et al. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR *Pseudomonas aeruginosa*. *J Antimicrob Chemother* **2018**; 73: 658–63.
 291. MacVane SH, Pandey R, Steed LL, et al. Emergence of ceftolozane-tazobactam-resistant *Pseudomonas aeruginosa* during treatment is mediated by a single AmpC structural mutation. *Antimicrob Agents Chemother* **2017**; 61:e01183–17.
 292. So W, Shurko J, Galega R, Quillitz R, Greene JN, Lee GC. Mechanisms of high-level ceftolozane/tazobactam resistance in *Pseudomonas aeruginosa* from a severely neutropenic patient and treatment success from synergy with tobramycin. *J Antimicrob Chemother* **2019**; 74:269–71.
 293. Zamudio R, Hijazi K, Joshi C, Aitken E, Oggioni MR, Gould IM. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant *Pseudomonas aeruginosa* from cystic fibrosis patients. *Int J Antimicrob Agents* **2019**; 53:774–80.
 294. Cabot G, Bruchmann S, Mulet X, et al. *Pseudomonas aeruginosa* ceftolozane-tazobactam resistance development requires multiple mutations leading to over-expression and structural modification of AmpC. *Antimicrob Agents Chemother* **2014**; 58:3091–9.
 295. Diaz-Canestro M, Perianez L, Mulet X, et al. Ceftolozane/tazobactam for the treatment of multidrug resistant *Pseudomonas aeruginosa*: experience from the Balearic Islands. *Eur J Clin Microbiol Infect Dis* **2018**; 37:2191–200.
 296. Boulant T, Jousset AB, Bonnin RA, et al. A 2.5-years within-patient evolution of a *Pseudomonas aeruginosa* with in vivo acquisition of ceftolozane-tazobactam and ceftazidime-avibactam resistance upon treatment. *Antimicrob Agents Chemother* **2019**; 63:e01637–19.
 297. Castanheira M, Mills JC, Farrell DJ, Jones RN. Mutation-driven beta-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible *Pseudomonas aeruginosa* isolates from U.S. hospitals. *Antimicrob Agents Chemother* **2014**; 58:6844–50.
 298. Rubio AM, Kline EG, Jones CE, et al. In vitro susceptibility of multidrug-resistant *Pseudomonas aeruginosa* following treatment-emergent resistance to ceftolozane-tazobactam. *Antimicrob Agents Chemother* **2021**; 65: e00084–21.
 299. Tamma PD, Beisken S, Bergman Y, et al. Modifiable risk factors for the emergence of ceftolozane-tazobactam resistance. *Clin Infect Dis* **2021**; 73:e4599–606.
 300. Khil PP, Dulanto Chiang A, Ho J, et al. Dynamic emergence of mismatch repair deficiency facilitates rapid evolution of ceftazidime-avibactam resistance in *Pseudomonas aeruginosa* acute infection. *mBio* **2019**; 10: e01822–19.
 301. Lahiri SD, Walkup GK, Whiteaker JD, et al. Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in *Pseudomonas aeruginosa* strains containing derepressed AmpC. *J Antimicrob Chemother* **2015**; 70: 1650–8.
 302. Gomis-Font MA, Cabot G, Sanchez-Diener I, et al. In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in *Pseudomonas aeruginosa*. *J Antimicrob Chemother* **2020**; 75:2508–15.
 303. Streling AP, Al Obaidi MM, Lainhart WD, et al. Evolution of cefiderocol non-susceptibility in *Pseudomonas aeruginosa* in a patient without previous exposure to the antibiotic. *Clin Infect Dis* **2021**; 73:e4472–4.
 304. Simner PJ, Beisken S, Bergman Y, Posch AE, Cosgrove SE, Tamma PD. Cefiderocol activity against clinical *Pseudomonas aeruginosa* isolates exhibiting ceftolozane-tazobactam resistance. *Open Forum Infect Dis* **2021**; 8:ofab311.
 305. Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B: similarities to and differences from colistin (polymyxin E). *Expert Rev Anti Infect Ther* **2007**; 5: 811–21.
 306. Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. *Clin Infect Dis* **2013**; 57:1300–3.
 307. Phe K, Lee Y, McDaniel PM, et al. *In vitro* assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. *Antimicrob Agents Chemother* **2014**; 58:2740–6.
 308. Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. *Int J Antimicrob Agents* **2014**; 43:349–52.
 309. Rigatto MH, Oliveira MS, Perdigo-Neto LV, et al. Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B. *Antimicrob Agents Chemother* **2016**; 60:2443–9.

310. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. *Diagn Microbiol Infect Dis* **2009**; 65:431–4.
311. Lu Q, Luo R, Bodin L, et al. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. *Anesthesiology* **2012**; 117:1335–47.
312. Kwa AL, Loh C, Low JG, Kurup A, Tam VH. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant *Acinetobacter baumannii* and *Pseudomonas aeruginosa*. *Clin Infect Dis* **2005**; 41:754–7.
313. Falagas ME, Siempos II, Rafailidis PI, Korbila IP, Ioannidou E, Michalopoulos A. Inhaled colistin as monotherapy for multidrug-resistant gram (-) nosocomial pneumonia: a case series. *Respir Med* **2009**; 103:707–13.
314. Choi HK, Kim YK, Kim HY, Uh Y. Inhaled colistin for treatment of pneumonia due to colistin-only-susceptible *Acinetobacter baumannii*. *Yonsei Med J* **2014**; 55:118–25.
315. Hsieh TC, Chen FL, Ou TY, Jean SS, Lee WS. Role of aerosolized colistin methanesulfonate therapy for extensively-drug-resistant *Acinetobacter baumannii* complex pneumonia and airway colonization. *J Microbiol Immunol Infect* **2016**; 49:523–30.
316. Kang CH, Tsai CM, Wu TH, et al. Colistin inhalation monotherapy for ventilator-associated pneumonia of *Acinetobacter baumannii* in prematurity. *Pediatr Pulmonol* **2014**; 49:381–8.
317. Chen YM, Fang WF, Kao HC, et al. Influencing factors of successful eradication of multidrug-resistant *Acinetobacter baumannii* in the respiratory tract with aerosolized colistin. *Biomed J* **2014**; 37:314–20.
318. Jean SS, Hsieh TC, Lee WS, Hsueh PR, Hsu CW, Lam C. Treatment outcomes of patients with non-bacteremic pneumonia caused by extensively drug-resistant *Acinetobacter calcoaceticus-Acinetobacter baumannii* complex isolates: is there any benefit of adding tigecycline to aerosolized colistimethate sodium? *Medicine (Baltimore)* **2018**; 97:e12278.
319. Tumbarello M, De Pascale G, Treccarichi EM, et al. Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria. *Chest* **2013**; 144:1768–75.
320. Kofteridis DP, Alexopoulou C, Valachis A, et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. *Clin Infect Dis* **2010**; 51:1238–44.
321. Korkmaz Ekren P, Toreyin N, Sayiner A, Bacakoglu F, Colistin Study G. The role of aerolized colistin in the treatment of hospital-acquired pneumonia: experience of multicenter from Turkey. *Crit Care Med* **2016**; 44:e304.
322. Demirdal T, Sari US, Nemli SA. Is inhaled colistin beneficial in ventilator associated pneumonia or nosocomial pneumonia caused by *Acinetobacter baumannii*? *Ann Clin Microbiol Antimicrob* **2016**; 15:11.
323. Abdellatif S, Trifi A, Daly F, Mahjoub K, Nasri R, Ben Lakhal S. Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial. *Ann Intensive Care* **2016**; 6:26.
324. Kim YK, Lee JH, Lee HK, et al. Efficacy of nebulized colistin-based therapy without concurrent intravenous colistin for ventilator-associated pneumonia caused by carbapenem-resistant *Acinetobacter baumannii*. *J Thorac Dis* **2017**; 9:555–67.
325. Michalopoulos A, Fotakis D, Virtzili S, et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant gram-negative bacteria: a prospective study. *Respir Med* **2008**; 102:407–12.
326. Kalin G, Alp E, Coskun R, Demiraslan H, Gundogan K, Doganay M. Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant *Acinetobacter baumannii* ventilator-associated pneumonia: do we really need this treatment? *J Infect Chemother* **2012**; 18:872–7.
327. Naesens R, Vlieghe E, Verbrugghe W, Jorens P, Ieven M. A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant *Pseudomonas aeruginosa*. *BMC Infect Dis* **2011**; 11:317.
328. Lin CC, Liu TC, Kuo CF, Liu CP, Lee CM. Aerosolized colistin for the treatment of multidrug-resistant *Acinetobacter baumannii* pneumonia: experience in a tertiary care hospital in northern Taiwan. *J Microbiol Immunol Infect* **2010**; 43:323–31.
329. Doshi NM, Cook CH, Mount KL, et al. Adjunctive aerosolized colistin for multidrug resistant gram-negative pneumonia in the critically ill: a retrospective study. *BMC Anesthesiol* **2013**; 13:45.
330. Mastoraki A, Douka E, Kriaras I, Stravopodis G, Manoli H, Geroulanos S. *Pseudomonas aeruginosa* susceptible only to colistin in intensive care unit patients. *Surg Infect (Larchmt)* **2008**; 9:153–60.
331. Berlanda D, Llop JM, Fort E, Badia MB, Jodar R. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. *Am J Health Syst Pharm* **2005**; 62:39–47.
332. Korbila IP, Michalopoulos A, Rafailidis PI, Nikita D, Samonis G, Falagas ME. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. *Clin Microbiol Infect* **2010**; 16:1230–6.
333. Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. *Crit Care* **2005**; 9:R53–9.
334. Ganapathy H, Pal SK, Teare L, Dziewulski P. Use of colistin in treating multi-resistant gram-negative organisms in a specialised burns unit. *Burns* **2010**; 36:522–7.
335. Falagas ME, Kasiakou SK, Kofteridis DP, Roditakis G, Samonis G. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. *Eur J Clin Microbiol Infect Dis* **2006**; 25:596–9.
336. Kuo SC, Lee YT, Yang SP, et al. Eradication of multidrug-resistant *Acinetobacter baumannii* from the respiratory tract with inhaled colistin methanesulfonate: a matched case-control study. *Clin Microbiol Infect* **2012**; 18:870–6.
337. Motaouakkil S, Charra B, Hachimi A, et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant *Acinetobacter baumannii*. *J Infect* **2006**; 53:274–8.
338. Jang JY, Kwon HY, Choi EH, Lee WY, Shim H, Bae KS. Efficacy and toxicity of high-dose nebulized colistin for critically ill surgical patients with ventilator-associated pneumonia caused by multidrug-resistant *Acinetobacter baumannii*. *J Crit Care* **2017**; 40:251–6.
339. Rattanaumpawan P, Lorsutthitham J, Ungpraser P, Angkasekwinai N, Thamlikitkul V. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by gram-negative bacteria. *J Antimicrob Chemother* **2010**; 65:2645–9.
340. Kollef MH, Ricard JD, Roux D, et al. A randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of gram-negative ventilator-associated pneumonia: IASIS trial. *Chest* **2017**; 151:1239–46.
341. Niederman MS, Alder J, Bassetti M, et al. Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial. *Lancet Infect Dis* **2020**; 20:330–40.
342. Boisson M, Jacobs M, Gregoire N, et al. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. *Antimicrob Agents Chemother* **2014**; 58:7331–9.
343. Rouby JJ, Bouhemad B, Monsel A, et al. Aerosolized antibiotics for ventilator-associated pneumonia: lessons from experimental studies. *Anesthesiology* **2012**; 117:1364–80.
344. Wenzler E, Fraidenburg DR, Scardina T, Danziger LH. Inhaled antibiotics for gram-negative respiratory infections. *Clin Microbiol Rev* **2016**; 29:581–632.
345. Biagi M, Butler D, Tan X, Qasmieh S, Wenzler E. A breath of fresh air in the fog of antimicrobial resistance: inhaled polymyxins for gram-negative pneumonia. *Antibiotics (Basel)* **2019**; 8:27.
346. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis* **2016**; 63:e61–111.
347. Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). *Pharmacotherapy* **2019**; 39:10–39.
348. Rello J, Sole-Leonart C, Rouby JJ, et al. Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. *Clin Microbiol Infect* **2017**; 23:629–39.
349. Maselli DJ, Keyt H, Restrepo MI. Inhaled antibiotic therapy in chronic respiratory diseases. *Int J Mol Sci* **2017**; 18:1062.